Abstract
GPCRs transform extracellular stimuli into a physiological response by activating an intracellular signaling cascade initiated via binding to G proteins. Orphan G protein-coupled receptors (GPCRs) hold the potential to pave the way for development of new, innovative therapeutic strategies. In this review we will introduce G protein-coupled receptor 143 (GPR143), an enigmatic receptor in terms of classification within the GPCR superfamily and localization. GPR143 has not been assigned to any of the GPCR families due to the lack of common structural motifs. Hence we will describe the most important motifs of classes A and B and compare them to the protein sequence of GPR143. While a precise function for the receptor has yet to be determined, the protein is expressed abundantly in pigment producing cells. Many GPR143 mutations cause X-linked Ocular Albinism Type 1 (OA1, Nettleship-Falls OA), which results in hypopigmentation of the eyes and loss of visual acuity due to disrupted visual system development and function. In pigment cells of the skin, loss of functional GPR143 results in abnormally large melanosomes (organelles in which pigment is produced). Studies have shown that the receptor is localized internally, including at the melanosomal membrane, where it may function to regulate melanosome size and/or facilitate protein trafficking to the melanosome through the endolysosomal system. Numerous additional roles have been proposed for GPR143 in determining cancer predisposition, regulation of blood pressure, development of macular degeneration and signaling in the brain, which we will briefly describe as well as potential ligands that have been identified. Furthermore, GPR143 is a promiscuous receptor that has been shown to interact with multiple other melanosomal proteins and GPCRs, which strongly suggests that this orphan receptor is likely involved in many different physiological actions.
Introduction
G protein-coupled receptor 143 (GPR143) is encoded by the ocular albinism 1 (OA1) gene, which was first cloned because of its role in the pathogenesis of ocular albinism, a disorder caused by dysfunction of pigment producing cells (Bassi et al., 1995). Lack of expression of functional GPR143 in pigment producing cells in the skin and hair (known as melanocytes) results in morphologic abnormalities of the organelles in which the pigment melanin is synthesized (known as melanosomes). The effects of pathogenic OA1 mutations are more consequential in the pigment cells of the eyes (including melanocytes and retinal pigment epithelium/RPE), resulting in severe reduction of visual acuity. Early studies of the protein were thus limited to melanocytes and RPE, however recent investigations have addressed a broader role for GPR143 as one of the few intracellular G protein-coupled receptors (GPCRs).
G protein-Coupled Receptor Related Structural Elements of GPR143
GPCRs, the largest family of membrane receptors, mediate almost all (patho)physiological functions in mammals (Fredriksson et al., 2003; Rosenbaum et al., 2009). Among the over 800 known GPCR gene sequences, approximately half encode receptors involved in sensory perception. Of the remaining non-sensory receptors, about 100 are orphan GPCRs (oGPCRs) for which either ligands and/or downstream signaling pathways are unknown (Fredriksson et al., 2003; Hauser et al., 2017; Harding et al., 2018). Since GPCRs have been established as a major class of protein that can be targeted by pharmaceuticals, deorphanization of oGPCRs may unlock valuable physiological information and provide new therapeutic approaches to improve human health (Rask-Andersen et al., 2014; Hauser et al., 2017; Jabeen and Ranganathan, 2019). GPR143 is one such oGPCR, an atypical receptor that is localized intracellularly in endolysosomes and melanosomes rather than the cell membrane where most other GPCRs function (O’Donnell et al., 1976; Samaraweera et al., 2001; Schiaffino and Tacchetti, 2005). Aside from assignment to a receptor family, the precise function of GPR143 still remains to be determined.
GPR143 and Its Relation to the GPCR Superfamily
From a structural perspective, all GPCRs display the same architecture—seven transmembrane alpha helices (TMs) connected by three intracellular and three extracellular loops (ICL1-3, ECL1-3). N-termini and C-termini, which the majority of GPCRs possess, can vary in length and in regulatory roles they play in GPCR signaling (Coleman et al., 2017; Odoemelam et al., 2020).
GPCRs can also be classified into subfamilies based on sequence homology. Vertebrate GPCRs can be subdivided by the GRAFS system (Glutamate, Rhodopsin, Adhesion, Frizzeled/Taste2, Secretin) (Fredriksson et al., 2003; Schiöth and Fredriksson, 2005; Alexander et al., 2017, 2019; Hu et al., 2017). Alternatively, a system of subdivision by functional similarities and sequence homology, which includes non-vertebrate GPCRs, has also been developed. GPCRs can be categorized into six classes by the ABC system: Class A—rhodopsin-like receptors, Class B—secretin family, Class C—metabotropic glutamate receptors, Class D—fungal mating pheromone receptors (non-vertebrate receptors), Class E—cAMP receptors (non-vertebrate receptors) and Class F—frizzled (FZD) and smoothened (SMO) receptors (Attwood and Findlay, 1994; Kolakowski, 1994; Hu et al., 2017). In order to classify a GPCR into a specific class it has to have been shown, by phylogenetic studies, that the candidate shares at least 20% sequence identity in the TMs, indicating likely evolution from a common ancestor (Alexander et al., 2019). A number of receptors, including GPR143, which do not display sufficient homology to known GPCR subfamilies remain to be assigned to a specific class.
Apart from sequence identity, the growing number of structure-function studies and resolved crystal structures have revealed that there are common structural and functional motifs which are crucial for the activation of each respective GPCR class (Latek et al., 2013; Moreira, 2014; Isberg et al., 2015; Zhou et al., 2019). In order to easily localize such motifs and to compare them to other GPCR classes, all GPCR residues can be annotated using the Ballesteros and Weinstein nomenclature (Ballesteros and Weinstein, 1995). Based on this nomenclature, the first digit identifies the TM helix and the second digit the residue position in relation to the most conserved residue of each TM helix (assigned index number 50). Numbers decrease towards the N-terminus and increase towards the C-terminus (Ballesteros and Weinstein, 1995; Moreira, 2014). We will briefly discuss the most prominent structural and functional motifs of class A and B receptors, which may be relevant for GPR143. Aside from class D and E receptors, which are only present in invertebrates, classes C and F do not display any similarities with GPR143. In addition we will highlight other residues, such as glycosylation sites and sorting signals. These key residues and features are annotated in Figure 1.
FIGURE 1
Protein sequence of GPR143 with highlighted features and residues. Grey: transmembrane domains (TM) as predicted by GPCRdb (Isberg et al., 2015, 2016; Kooistra et al., 2021); yellow: potential glycosylation sites N106 in ECL1 and N263 in ECL3 (Samaraweera et al., 2001); green: highly conserved cysteine residue in TM3 (C3.25) which might form a disulfide bond with C184 in extracellular loop 2 (ECL2); red: sorting signals for intracellular localization (dileucine motif (L223/L224) in the intracellular loop 3 (ICL3) and tryptophan-glutamic acid doublet (W329/E330) in the C terminal tail) (Piccirillo et al., 2006). Conserved residues found in class A GPCRs or similar motifs are bold, italic and underlined, motifs common in class B GPCRs are bold and italic, residues known to cause ocular albinism type 1 when mutated are marked with an asterix (for references see main text).
Key Residues Relevant for GPR143
GPR143, the protein product of the OA1 gene, was found to span the plasma membrane seven times, indicating that it could be a potential GPCR as far back as 2007 when the 404 amino acid length protein, was classified as orphan receptor GPR143 (Sone and Orlow, 2007). Here we summarize the key residues found in class A and B receptor families and compare them to GPR143, as early studies by Schiaffino et al. demonstrated that the receptor shows weak similarities with classes A and B (Schiaffino et al., 1999) (see Figure 1). Similar findings were described by Gosh et al. who investigated GPR143 using a 3-dimensional modeling approach (Gosh at al., 2012). In the IUPHAR guide to pharmacology, GPR143 is still listed in the family of “other 7 TM proteins” (Alexander at al., 2019; http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=203, accessed on 9 February 2022) and in the GPCRdb it is listed among “other GPCR orphans” (Kooistra et al., 2021).
The structural and functional motifs that define class A are the most extensively studied with relation to their activation mechanism. Class A GPCRs, also referred to as rhodopsin receptors, include many functionally diverse receptor members. Diverse physiological actions such as inter- and intracellular communication, sense of sight, smell taste and touch, chemotaxis and neurotransmission are mediated through class A GPCRs (
Fredriksson et al., 2003;
Mombaerts, 2004;
Moreira et al., 2010;
Moreira, 2014;
Isberg et al., 2016). According to Zhou
et al.(
Zhou et al., 2019) and numerous other studies (for example, (
Moreira, 2014;
Filipek, 2019), the most important (and conserved) motifs are:
1) The interaction of the cytoplasmic “ionic lock” in TM3, which is disrupted when the receptor is activated with the consensus “(D/E)R (Y/M)” (3.49–3.51) with D/E (6.30) in TM6 (Ballesteros et al., 1998, 2001; Schneider et al., 2010; Jacobson et al., 2014; Yuan et al., 2014; Feng et al., 2017; Roth et al., 2017; Schönegge et al., 2017; Alhadeff et al., 2018); the characteristic DRY motif in TM3 is DAY in GPR143 (Ghosh et al., 2012), while the counterpart in TM6 D/E 6.30 is G in GPR143.
2) The hydrophobic arginine cage around the conserved arginine (R3.50) of the DRY motif, which restrains its conformation in the inactive state of the receptor consisting of two hydrophobic amino acids (such as L, V, I or M) in TM3 and TM6 (3.46, 6.37) (Ballesteros et al., 1998; Visiers et al., 2002; Weinstein, 2006; Caltabiano et al., 2013); the arginine cage is not present in GPR143.
3) The NPxxYxF motif in TM7, which forms the interaction of a tyrosine (7.53) in TM7 with the phenylalanine (7.60) in HX8 together with the side chain and backbone of an arginine in TM2 (2.40) through binding of a water molecule (Prioleau et al., 2002; Fritze et al., 2003; Angel et al., 2009; Hofmann et al., 2009; Rasmussen et al., 2011; Trzaskowski et al., 2012; Venkatakrishnan et al., 2016; Schönegge et al., 2017; Filipek, 2019); this motif is partially found in GPR143 represented by N7.41and P7.42 (Ghosh et al., 2012), however the tyrosine in the motif is missing in GPR143, only the conserved Y7.53 is found.
4) A coordinated conformational change upon ligand coupling of aromatic residues in TM6, also known as CWxP motif around a very conserved tryptophan (6.48) that leads to disruption of the ionic lock and outward movement of TM6 (called Rotamer Toggle Switch), while TM7 undergoes inward movement towards TM5 (Weinstein, 2006; Hofmann et al., 2009; Nygaard et al., 2009; Holst et al., 2010; Standfuss et al., 2011; Trzaskowski et al., 2012; Valentin-Hansen et al., 2012; Tehan et al., 2014; Zhang et al., 2015; Venkatakrishnan et al., 2016; Plazinska et al., 2017; Eddy et al., 2018; Kaiser et al., 2018; Filipek, 2019); instead of CWxP, CWLS is found in GPR143 in the same position (Ghosh et al., 2012).
5) The PIF motif comprising residues P5.50, I3.40 and F6.44 (Ballesteros and Weinstein, 1995; Ishchenko et al., 2017; Schönegge et al., 2017; Kato et al., 2019; Hilger, 2021; Smith, 2021); the PIF motif is also not present in GPR143, only P5.50 itself is found.
6) The Na+-pocket at a conserved aspartic acid (2.50) (Liu et al., 2012; Yuan et al., 2013; Zhang et al., 2013; Katritch et al., 2014; Eddy et al., 2018; Vickery et al., 2018; White et al., 2018; Ye et al., 2018; Chen S. et al., 2019; Filipek, 2019; Agasid et al., 2021); D2.50 important for Na+ binding is also present in GPR143.
Some of the conserved residues in the helix packing clusters of class A GPCRs are also found in GPR143 (G/S1.46, A2.47, A3.38, S/A4.53, P5.50), however GPR143 does not contain all of the described switches (Sanchez-Reyes et al., 2017). The conserved disulfide bond between C3.25 on TM3 and C184 (ECL2), common in most GPCRs, is also found in the GPR143 sequence (Venkatakrishnan et al., 2013), see Figure 1.
Adhesion and secretin receptors were initially classified as two distinct families, however the secretin GPCRs were later shown to have some structural resemblance to adhesion GPCRs and through phylogenetic analysis it was determined that secretin GPCRs evolved from adhesion GPCRs (Nordström et al., 2009; Hamann et al., 2015). The secretin receptor family was labeled class B1 and the adhesion receptor family class B2 (Pándy-Szekeres et al., 2018; Scholz et al., 2019).
Distinct from class A receptors, secretin receptors possess a very large N-terminus, which is also called extracellular domain (ECD) that is important for ligand recognition and activation of the receptor together with the TM domains (Hoare, 2005; Parthier et al., 2009; Pal et al., 2012; Ramos-Álvarez et al., 2015; Karageorgos et al., 2018). The ECLs and the upper regions of the TMs form the so-called “J domain” of class B receptors (Karageorgos et al., 2018). GPR143 does not have an ECD, however it may have been lost in evolution, since remnants of at least one former OA1 exon is still found on the Y chromosome (Van Laere et al., 2008; Pandey et al., 2013) (see chapter “Evolutionary Aspects”).
Only a few studies have attempted to investigate adhesion receptors from a pharmacological perspective, such as through mutational studies (Peeters et al., 2016; Nazarko et al., 2018; Arimont et al., 2019; Beliu et al., 2021). From these studies important residues and from sequence alignments with sequences from class A and B1 relevant residues in class B2 receptors have been identified (Nijmeijer et al., 2016; Arimont et al., 2019). For instance, most class B1 conserved residues are also present in class B2 such as S1.50 (1.46 in class A), H2.50 (2.43 in class B1), E3.50 (3.46 in class A), W4.50 (4.50 in class A), N5.50 (5.54 in class A), G6.50 (6.45 in class A) and G7.50 (7.46 in class A) (Wootten et al., 2013; Nijmeijer et al., 2016; Arimont et al., 2019). Furthermore, a conserved proline residue of TM5 of secretin receptors P5.42 can also be found in adhesion receptors as well as a conserved tryptophan at position 6.53 which is similar to the conserved tryptophan at position 6.48 in class A GPCRs which is part of the CWxP motif and may act as potential toggle switch as seen for class A (Nijmeijer et al., 2016; Plazinska et al., 2017; Ping et al., 2021). The conserved P5.42 is one of the few residues GPR143 has in common with class B receptors as well as the highly conserved W4.50 found in class A and B.
Other Structural Features
GPR143 possesses two distinct sorting signals for lysosomal and melanosomal localization, a dileucine motif in ICL3 and a tryptophan-glutamic acid doublet in the C terminal tail. Both are essential and sufficient for localization to organelles (Piccirillo et al., 2006). When mutated to alanine residues, the receptor is primarily localized to the plasma membrane (Piccirillo et al., 2006; De Filippo et al., 2017b). In addition to the sorting signals, Giordano et al. demonstrated that GPR143 intracellular sorting and ubiquitination are dependent upon functional components of endosomal sorting complexes required for transport (ESCRT) complex (Giordano et al., 2011). Intracellular sorting and down-regulation were also associated with the amount of ESCRT-0, -I, and -III subunits, as their depletion or overexpression inhibited GPR143 degradation together with retention in the endosomal system (Giordano et al., 2011). Giordano and co-workers hypothesized, based on their results, that the ESCRT machinery ubiquitinates GPR143 in intralumenal vesicles of multivesicular endosomes thereby allowing for modulation between downregulation and GPR143 delivery to melanosomes (Giordano et al., 2011).
The receptor also contains two potential glycosylation sites, one in ECL1 (N106) and the second in ECL3, however evidence for glycosylation has only been shown for N106 (Samaraweera et al., 2001) (see Figure 1).
Evolutionary Aspects
In the gene (NG_009074.1) and nucleotide (NM_000273.3) databases GPR143 is referenced with 9 exons, of which 7 contain coding sequence regions and the protein is 404 amino acids long (NP_000264.2; UniProt ID P51810). Several shorter isoforms of the protein have been predicted, e.g., isoform X1 (XP_005274598.1) with 386 amino acids and isoform X2 (XP_024308155.1) with 320 amino acids.
The OA1 gene is located on chromosome Xp22.2. Adjacent to GPR143, at the same chromosomal location, is SHROOM2, which is also highly expressed in the retina and may also be associated with ocular defects, similar to GPR143 (Van Laere et al., 2008; Pandey et al., 2013). Interestingly, it may contain one or more non-coding GPR143 exons which were lost during evolution. Mammalian sex chromosomes evolved from homologous autosomes after a series of recombination suppression and inversion events that rendered the Y chromosome relatively short. So-called “small pseudoautosomal regions” remain on the Y chromosome and can be mapped to distinct evolutionary strata (Van Laere et al., 2008; Pandey et al., 2013). Pseudogenes of the SHROOM/GPR143 gene cluster are still present on the Y chromosome (Van Laere et al., 2008).
GPR143 Function
GPCRs typically transform extracellular stimuli into a physiological response by activating an intracellular signaling cascade initiated by binding to G proteins. Regarding GPR143, little is known about its intracellular signaling or its binding of ligands, most probably due to its unique localization within the cell. However, a few studies have identified potential ligands for GPR143. The topological orientation of the receptor suggests that ligands would have to bind from the organelle lumen (Sone and Orlow, 2007; Schiaffino, 2010).
Potential GPR143 Ligands
L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine have been proposed as ligands by Lopez et al. in 2008 (Lopez et al., 2008). While L-DOPA is an intermediate compound in the biosynthesis of melanin and the conversion of L-tyrosine to L-DOPA the rate-limiting step of the process (D’Mello et al., 2016), dopamine is not part of the synthesis but can be produced through hydroxylation of L-DOPA (Daubner et al., 2011). In addition, Staleva and Orlow suggested, based on their results in a yeast-based study, that activating compounds or proteins for GPR143 may be located in the 100,000 g fraction of cultured, heavily pigmented melanocytes, which contains melanosomes (Staleva and Orlow, 2006).
In radioligand-binding experiments an equilibrium dissociation constant (Kd) of 9.35 µM for L-Dopa and a Kd of 2.39 µM for dopamine were obtained (Lopez et al., 2008). By measuring the intracellular calcium release through Gq/11 protein coupling in CHO cells, only L-DOPA was shown to activate GPR143, while dopamine displayed antagonist properties instead. After treatment with L-DOPA GPR143 and β-Arrestin colocalized at the plasma membrane, indicating that GPR143 is able to change its localization in a ligand-dependent manner (Lopez et al., 2008). In another study by Hiroshima et al., a Kd of 79.1 µM was measured for L-DOPA using murine GPR143, but only in RPE-derived cells, while no calcium release was detected in CHO cells. The authors further reported that the binding of L-DOPA to murine GPR143 was competitively antagonized by L-DOPA cyclohexyl ester (DOPA-CHE) (Hiroshima et al., 2014). Since the discovery of L-DOPA as potential ligand for GPR143, many studies have been conducted based on this finding, for example clinical studies to evaluate L-DOPA as a therapy for ocular albinism, which were not conclusive (Summers et al., 2014). Although it is most likely that GPR143 is a receptor for L-DOPA, there are also contradictory findings (see below).
Goshima and co-workers, who performed microinjections into the nucleus tractus solitarius (NTS) to investigate cardiovascular actions of L-DOPA through GPR143, could not exclude that dopamine converted from L-DOPA in non-neuronal tissues would be also able to exert cardiovascular and/or renal actions through β-adrenergic receptor and dopamine receptors D1R and D2R (Goshima et al., 2014). It was shown that D1R activity in vascular smooth muscle is associated with vasodilatation (Kohli, 1990). Moreover D2R were shown to exert their effects on sympathetic nerve terminals which resulted in a decrease of noradrenaline release (Dubocovich and Langer, 1980). Also effects on renal blood flow, glomerular filtration rate, urinary sodium, and water excretion as well as promotion of phosphate excretion and antagonizing the hydro-osmotic effect of vasopressin were described (Goshima et al., 2014).
In addition, a study by Ueda et al. showed that L-DOPA (10–100 mg/kg, i.p.) induced ptosis in wildtype (WT) and GPR143-knockout (KO) mice, which were pretreated with 3-hydroxybenzylhydrazine, a central aromatic L-amino acid decarboxylase inhibitor, used to prevent conversion of L-DOPA to dopamine (Ueda et al., 2016; Goshima et al., 2019a). Ptosis, which is also called “lazy eye,” is described as the falling or dropping of the upper eyelid (Finsterer, 2003). Similar malfunctioning of the motoric system (“motor blocks”) can sometimes result from either short- or long-term L-DOPA treatment of Parkinson’s disease (Giladi et al., 1992; Dewey and Maraganore, 1994; Goshima et al., 2019a). Since L-DOPA induced ptosis in both WT and GPR143-KO mice, the authors suggest that there may be GPR143-dependent and independent mechanisms for inducing ptosis (Ueda et al., 2016; Goshima et al., 2019a).
In 2017 De Filippo et al. used a high throughput screening (HTS) approach to identify new pharmacological tools for further investigation of GPR143 signaling (De Filippo et al., 2017a). Due to the intracellular localization of GPR143 a mutant was created, which localized to the plasma membrane (Piccirillo et al., 2006), in order to ensure that concerns about test compounds permeating into the cells and reaching the receptor were addressed. The β-Arrestin recruitment assay was chosen as a suitable assay for HTS screening since GPR143 showed high constitutive activity, while the melanin assay was chosen to validate potential candidates. Pimozide, niclosamide and ethacridine lactate were identified as new inverse agonists for GPR143, however are yet to be independently confirmed. Pimozide is a dopamine receptor D2R and D3R-antagonist (Schwinn et al., 1976; Sokoloff et al., 1992), niclosamide was described as anthelmintic teniacide with antitumor activity (Pan et al., 2012) and ethacridine lactate as an antiseptic. In the same study by De Filippo et al. no Ca2+ response following L-DOPA stimulation could be observed in CHO cells, which is in contradiction to the findings by Lopez et al. (Lopez et al., 2008; De Filippo et al., 2017a). To further characterize GPR143 and understand its actions there is a need for the discovery of new, highly potent compounds as pharmacological tools.
GPR143 Signaling Pathways
Schiaffino et al. showed that GPR143 associates with several Gα subunits and Gβ (Schiaffino et al., 1999; Schiaffino and Tacchetti, 2005). Furthermore, Innamorati et al. discovered that GPR143 also associates with β-Arrestin, even in the absence of a ligand (Innamorati et al., 2006). This finding was further confirmed by De Filippo et al. who also showed ligand-independent β-Arrestin recruitment in an in vitro assay system (De Filippo et al., 2017a). Moreover, a study by Lopez et al. who also discovered L-DOPA as potential ligand for GPR143, observed an influx of intracellular calcium and recruitment of β-Arrestin, when cells were treated with L-DOPA at high concentrations (Lopez et al., 2008). McKay et al. showed that myocilin plays a role in ligand-dependent β-Arrestin-recruitment to GPR143, which leads to endocytosis (McKay et al., 2013).
In 2008, a study by Young et al. investigated the relationship between GPR143 and the Gαi family comprising the closely-related members, Gαi1, Gαi2, and Gαi3 (Young et al., 2008). The Gαi proteins also locate to intracellular membranes including Golgi and endosomal membranes (Gohla et al., 2007; Young et al., 2008) and were found to be associated with membrane trafficking and fusion events (Young et al., 2008). In addition, Gαi3 is expressed in fetal and adult human RPE cells and the inner neural retina (Jiang et al., 1991; Oguni et al., 1996; Young et al., 2008). By studying the RPE density and morphology of melanosomes of Gαi3−/− and GP143−/− knockout mice, the authors were able to observe the same phenotype in both mice genotypes (Young et al., 2008). Furthermore Young and co-workers investigated routing of the optic tract, which is established during development and disrupted in ocular albinism. Both Gαi3−/− and GP143−/− knockout mice were found to have the same optic nerve misrouting, which suggests that GPR143 signaling may be executed through Gαi3 (Young et al., 2008). Hence, it was suggested that a potential GPR143-Gαi3 signaling cascade is involved in the correct routing of axons through the optic chiasm and that Gαi3 is part of the same signal transduction pathway as GPR143, which also regulates melanosome biogenesis (Young et al., 2008). Besides Gai3, also Go and Gq were suggested as potential G proteins partners for GPR143 (Young et al., 2008).
GPR143 may also play a role in melanomagenesis and melanoma progression. Stimulation of the RAS/RAF/mitogen activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway by the Epidermal Growth Factor (EGF) and Platelet Derived Growth Factor (PDGF), which play a role in proliferation and survival of tumor cells, resulted in enhanced GPR143 expression and migration of the melanoma cells (Bai et al., 2014).
Expression and Localization of GPR143
GPR143 is most abundantly expressed in pigment producing cells in the skin and eyes. The pigment produced by these cells is melanin, which plays a central role in protecting human skin and eyes from the deleterious effects of ultraviolet light (UV). Pigment cells and melanin are also required for normal development of the optic system and function of the eye (Williams, 2018). Pigment cells in the skin and eyes are continually subjected to environmental stimuli including UV, visible light and chemotoxins. These stimuli can instigate cellular changes that lead to tumorigenesis (Gilchrest et al., 1999) and age-related macular degeneration (Xia et al., 2019).
Epidermal melanocytes produce melanin in the skin and hair, and RPE in the eye. RPE are required for photoreceptor function and formation of the blood–retinal barrier (Strauss, 2005). Melanocytes are also found in mucosal tissues, the inner ear, eyes and brain (Yamaguchi and Hearing, 2014).
Melanin is produced in membrane-bound organelles called melanosomes. Melanosome biogenesis is a de novo process involving four stages of maturation (Seiji et al., 1963). Melanosomes originate from endolysosomal structures (Raposo et al., 2001) and share a lineage with lysosomes (Orlow, 1995). In melanocytes, GPR143 localizes to the melanosomal membrane. When expressed exogenously in non-pigmented cells GPR143 localizes to lysosomes, e.g. in CHO, COS7 or HeLa cells (Schiaffino et al., 1999; Shen et al., 2001; Piccirillo et al., 2006; De Filippo et al., 2017b). However, the intracellular localization was questioned by McKay et al. in a commentary in relation to the paper by De Filippo et al. (De Filippo et al., 2017b; McKay et al., 2017). McKay at al. claimed that intracellular localization was only due to tyrosine present in culture media and that lack of Ca2+ response was also due to presence of tyrosine which acts as a weak antagonist (McKay et al., 2017). De Filippo et al. presented, in an author response, further data that supported their finding of intracellular localization even in tyrosine-free medium, as well as lack of Ca2+ response in medium without tyrosine (De Filippo et al., 2017c). Intracellular localization in heterologous systems was also shown by other groups as stated above (Schiaffino et al., 1999; Shen et al., 2001; Piccirillo et al., 2006).
Aside from the lack of defined function for GPR143, the expression profile of the receptor in different tissues, apart from the skin and eyes, is also poorly delineated. Fukuda et al. showed in mice, GPR143 is highly expressed in several regions of the brain including pyramidal neurons in the cerebral cortex (Fukuda et al., 2015). By using RT-PCR, GPR143 mRNA was detected in the central nervous system, olfactory bulb, corpus striatum, hypothalamus, hippocampus, midbrain, cerebellum and lower brain stem. While the highest expression was observed in the cerebral cortex and hypothalamus; moderate expression was shown in the olfactory bulb, hippocampus, midbrain and lower brain stem and lastly, low expression was seen in the corpus striatum and cerebellum (Fukuda et al., 2015). The receptor was also found to be expressed in the habenular nucleus, substantia nigra, medulla oblongata and NTS (Fukuda et al., 2015). In addition, Masukawa et al. performed an immunohistochemical analysis of GPR143 expression in the adult rat brain (Masukawa et al., 2014). GPR143-immunoreactive cells were found in the hippocampus, cerebral cortex, cerebellum cortex, striatum, substantia nigra, hypothalamic median eminence and supraoptic nucleus, NTS and caudal ventrolateral medulla and rostral ventrolateral medulla, medial habenular nucleus and olfactory bulb. Outside the brain GPR143 was found in the lungs, heart, kidneys, spleen and liver. The expression of the receptor in the kidney was most abundant and comparable to expression in the cerebral cortex and hypothalamus (Fukuda et al., 2015).
At the cellular level, GPR143 was found in cell bodies of pyramidal neurons, also excitatory neurons and various nuclei such as the NTS can express the receptor. Regarding non-neuronal expression of GPR143, Fukuda et al. discovered GPR143-positive cells in the convoluted tubules in the kidney, in the splenic capsule and red pulp of the spleen, hepatocytes around the hepatic vein of the liver, alveolar epithelial cells and bronchial tubes of the lung, smooth muscle cells around the respiratory bronchiole as well as in the basal lamina and connective tissues in their immunostaining experiments. Interestingly, expression of GPR143 throughout the body overlaps, in most parts, with the expression pattern of dopamine, angiotensin and adrenergic receptors, which are all involved in sympathetic signaling (Fukuda et al., 2015).
GPR143 and Diseases
GPR143 Role in Melanocytes and Ocular Albinism
Albinism refers to a group of genetic conditions associated with hypopigmentation (Bassi et al., 1995). The disorder can affect the skin, hair and eyes (oculocutaneous albinism) or only the eyes (ocular albinism). Several forms, defined by the mutated gene, exist, among them Ocular Albinism Type 1 (OA1) (Bassi et al., 1995; Shen et al., 2001). OA1, also called X-linked ocular albinism of the Nettleship-Falls type has a prevalence of 1–9/1 000 000 and an estimated birth prevalence of 1/60 000 to 1/150 000 live male births (https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=54&lng=EN, accessed 3 January 2022). Since OA1 is inherited in an recessive X-linked manner it affects mostly males. Heterozygous females can manifest a less severe phenotype (Falls, 1951; Lang et al., 1990; Preising et al., 2001; Shen et al., 2001). The OA1 phenotype is defined by significant reduction of visual acuity, nystagmus, strabismus, marked photophobia and loss of stereoscopic vision due to misrouting of the optic tract (Creel et al., 1990; Kriss et al., 1992; Bassi et al., 1995). In addition, iris translucency, foveal hypoplasia and hypopigmentation of the retina (O’Donnell et al., 1976; Bassi et al., 1995) is evident upon ophthalmologic examination of OA1 patients. Nystagmus, which is observed at around 6 months after birth, can be the first indication of ocular albinism (Liu et al., 2007; Mao et al., 2021). Female carriers display a mosaic pattern of ocular (hypo)pigmentation as a result of the inactivation of the affected X chromosome (Falls, 1951; Lang et al., 1990).
At the cellular level, the most prominent feature of OA1 is the formation of macromelanosomes (O’Donnell et al., 1976; Garner and Jay, 1980; Wong et al., 1983; Yoshiike et al., 1985). Consequently, OA1 can be seen as a systemic disorder affecting the biogenesis of melanosomes (Traboulsi, 2012). Despite affecting melanosome morphology, effects of OA1 mutations on the skin appear to be mild (Bassi et al., 1995).
Mutations or loss of function (LoF) in the OA1 gene (GPR143) results in OA1 (Shen et al., 2001). Moreover, the severity of OA1 is associated with the degree of skin pigmentation, with symptoms more severe in individuals whose skin are lightly pigmented and less severe in individuals with highly pigmented skin (O’Donnell, 1978; Shiono et al., 1995). The incidence of ocular albinism also varies between populations (Zhu et al., 2018). To date, over 300 OA1 point mutations have been identified and 60 of them were reported to result in OA1 (Figure 2 and Supplementary SI, Supplementary Table S1). While most mutations lead to the characteristic OA1-phenotype (red), three residues were identified which, when mutated, lead to a mild form of OA1 (blue). Furthermore, two residues associated with both mild and severe phenotypes were described (green) (Figure 2). Aside from point mutations several pathogenic splicing mutations, small insertions and deletions as well as the deletion of entire exons and other complex mutations were reported (Supplementary Tables S2–6). We collected over 500 mutations for GPR143 taken from literature, the gnomAD_v2.1.1 database (Karczewski et al., 2020), the Albinism database (http://www.ifpcs.org/albinism/oa1mut.html, accessed 12.01.2022), and the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php, accessed 01.02.2022), however it should be noted that the functional effects of the mutants is unknown (or benign) and presumably most exist in the germline of normal populations.
FIGURE 2
Protein sequence of GPR143 showing pathogenetic point mutations which lead to the OA1 phenotype (red) and mutations which cause a mild variant of OA1 (blue). For some mutated amino acids, either strong or weak OA1 phenotypes were reported (green). The snake plot was created using GPCRdb (Kooistra et al., 2021).
Regarding the point mutations we identified six specific residues which were found to be mutated more than twice: P1.20/P4 (4x), G2.53/G81 (3x), G2.56/G84 (3x), C3.25/C116 (4x), G3.27/G118 (4x), and W292 (ECL3) (5x). Moreover, when comparing the types of mutated residues we found that glycine and alanine residues were mutated more than 30 times, while phenylalanine was only mutated twice (Figure 3A). When mutated amino acids were sorted by topological domains it becomes obvious that most mutations occur in the C-terminus, while the least frequently mutated ones were found in the ICL1 and ICL2 as well as in the proposed HX8 region (Figure 3B). When comparing the number of mutations within TMs, particularly TM1 and TM3 were most likely to comprise mutated residues, while residues in TM7 were the least affected by mutations (Figure 3B). Some of the mutated residues are highly conserved residues, such as D2.50, C3.25, P5.50 (Figure 1, residues labeled with an asterisk).
FIGURE 3
Mutated amino acids affected by point mutations for G protein-coupled receptor 143 sorted by type (A) and sorted by topological domain (B).
Mutations in the genes coding for GPR143 and FERM domain-containing 7 (FRMD7), both found on the X-chromosome, have been linked to congenital nystagmus, one of features of ocular albinism that can occur as a non-syndromic condition (Han et al., 2015; Michaud et al., 2019; Wang et al., 2021).
GPR143 and Cardiovascular Actions
GPR143 has recently been shown to play a role in cardiovascular function through the (NTS) (Goshima et al., 2014; 2019a). The NTS is a sensory nucleus embedded in the medulla oblongata (Šimić, 2019) that receives signals from the solitary tract including facial, taste, gastrointestinal and cardio-respiratory signals (Geerling and Loewy, 2006; Michael Conn, 2008; Zoccal et al., 2014; Šimić, 2019; Martinez and Kline, 2021). Studies by Hiroshima et al. suggest that GPR143 serves as an L-DOPA receptor for cardiac response in the NTS. When GPR143 expression was repressed in the NTS, depressor and bradycardic responses to L-DOPA were suppressed (Hiroshima et al., 2014). They further demonstrated that L-DOPA, but not dopamine, produced these cardiovascular effects (Yue et al., 1994; Goshima et al., 2014; Hiroshima et al., 2014).
Masukawa et al. proposed a fine-tuning system of noradrenaline signaling for the regulation of blood pressure through L-DOPA possibly mediated by GPR143. Disruption of this regulation might lead to a number of effects including hypertension, arrhythmia, and other cardiovascular diseases (Masukawa et al., 2017). In addition, GPR143 may also interact with the α1b-adrenoceptor. In vitro studies using HEK293 cells co-expressing the two proteins confirmed that interaction between GPR143 and α1b-adrenoceptor was enhanced by L-DOPA (10–20 nM) treatment in immunoprecipitation assays (Masukawa et al., 2017). They further showed in Förster Resonance Energy Transfer (FRET) and in situ proximity ligation assay experiments that GPR143 and α1b-adrenoceptor form functional heteromers and that GPR143 has a higher affinity for L-DOPA in the heteromer as compared to the monomeric form (Masukawa et al., 2017). Nakano et al. suggested that α1b-adrenoceptor and GPR143 may play a role in the pathology of pulmonary hypertension (Nakano et al., 2022).
GPR143 in the Central Nervous System
GPR143 is widely expressed in neurons in several regions of the brain (Masukawa et al., 2014; Fukuda et al., 2015) and may play a role in the etiology of Parkinson’s disease (PD). L-DOPA is the most effective therapeutic for PD. It was developed as an inactive precursor for dopamine, which would be delivered to the brain to compensate for dopamine deficiency (Hornykiewicz, 2006; Goshima et al., 2019a). L-DOPA is then converted to dopamine in the brain by aromatic L-amino acid decarboxylase and alleviates motoric symptoms of PD such as akinesia, tremor, rigidity and bradykinesia (Xia and Mao, 2012; Moustafa et al., 2016).
Goshima et al., and others, have presented evidence that L-DOPA is able to induce independent signaling routes apart from dopamine, for example in regulating cardiovascular activity (Goshima et al., 1986, 1988, 2014, 2019a; Kubo et al., 1992; Yue et al., 1994). Since L-DOPA is a potential ligand for GPR143, Goshima et al. proposed that L-DOPA itself, rather than dopamine, may function as a neurotransmitter via this receptor (Goshima et al., 1988, 2019a, 2019b; Nakamura et al., 1992). According to their studies, GPR143 colocalized with phosphorylated α-synuclein in Lewy bodies in the brains of PD patients (Goshima et al., 2019b). These Lewy bodies are abnormal protein aggregates and the presence of GPR143 in these inclusion bodies could alter activity of the receptor and dysregulate L-DOPA signaling. Alternatively, given the proposed role for GPR143 in organelle biogenesis in melanocytes, the presence of GPR143 may be due to its participation in endolysosomal protein trafficking.
Goshima et al. also observed GPR143-immunoreactive signals, in both control and PD brains, in the entire midbrain region including the substantia nigra pars compacta (Goshima et al., 2019b), a basal ganglia structure and contains dopaminergic neurons that produce neuromelanin (Rabey and Hefti, 1990). The loss of these dopaminergic neurons is characteristic of PD (Kim et al., 2003). Taken together, Goshima and co-workers suggest that GPR143 may be implicated in the pathogenesis of PD and could be targeted for development of therapeutics (Goshima et al., 2019a).
In a very recent publication Kasahara et al. present evidence that L-DOPA-induced neurogenesis in the hippocampus of mice that might be mediated by GPR143 (Kasahara et al., 2022). Lastly, GPR143 was also found to be upregulated together with other genes in autism spectrum disorder (Monfared et al., 2021).
GPR143 and Macular Degeneration
Age-related macular degeneration (AMD), a multifactorial disease, leads to progressive vision loss (Lim et al., 2012; Mitchell et al., 2018). In early stages, RPE abnormalities are observed in the macular region of the retina followed by neovascular changes and finally total blindness (Coleman et al., 2008; Mitchell et al., 2018). Highly effective anti-neovascular agents such as vascular endothelial growth factor (VEGF)-inhibitors, applied by ocular injections, are used to treat AMD (Coleman et al., 2008; Lim et al., 2012; Bourne et al., 2013). Development of alternative treatments that require less invasive administration routes is therefore necessary (Figueroa and McKay, 2019).
An early study by Zhang et al. determined that Pigment Epithelium-Derived Factor (PEDF) can downregulate VEGF since decreased PEDF levels in the retina were shown to increase VEGF expression (Zhang et al., 2006). It was later discovered that there is extensive crosstalk between VEGF and PEDF that contributes to a neuroprotective effect (Falk et al., 2010).
PEDF was also found to be highly expressed in the RPE of young adults, with expression rapidly decreasing with onset of cell senescence (Tombran-Tink et al., 1995). In a study by Lopez et al., RPE cells were treated with high concentrations of L-DOPA and were shown to increase PEDF expression, which was attributed to GPR143 activity (Lopez et al., 2008). Furthermore, a retrospective study analyzing the medical history of AMD-patients found that those who were or had been on an L-DOPA regimen for movement disorders showed a later onset of AMD than those who had not received similar medication (Brilliant et al., 2016). If modulation of GPR143 could be employed to increase PEDF expression and thereby downregulate VEGF, the receptor has potential as a new target for the treatment of AMD (Falk et al., 2012).
GPR143 and Cancer
In 2020, around 10 million deaths were accounted for from cancer worldwide and with an estimation of 11.4 million deaths in 2030, cancer is a leading cause of death (O’Callaghan, 2011; Ferlay et al., 2021). Several GPCRs have been linked to different cancers and their role in regulating tumorigenesis, proliferation, invasion and metastasis is slowly being defined. GPR143 has also been associated with multiple cancers including melanoma, non-melanoma skin cancer, breast cancer, uveal carcinoma, colorectal cancer (Bassi et al., 1995; Uhlén et al., 2015; Uhlen et al., 2017). In a recent bioinformatic analysis investigating unilateral and bilateral retinoblastoma microarrays, GPR143 was identified as a potential biomarker for the cancer (Zhao et al., 2021).
Melanoma and Skin Cancer
Malignant melanoma is one of the most aggressive cancers, with a highly metastatic potential and a predilection for developing resistance to therapies (Bai et al., 2014). Furthermore, in the US, melanoma is the sixth most common cancer type (Borden et al., 2021). Despite substantial efforts to develop targeted therapies, long-term success remains challenging (Li et al., 2011; Kozar et al., 2019; Alvarez-Artime et al., 2020; Berge et al., 2020; Cherepakhin et al., 2021).
GPR143 expression has been shown to correlate with prognosis in cutaneous melanoma and is a reliable biomarker for identifying immune infiltration (Xing et al., 2021). In addition, when Bai et al. used lentivirus constructs to express exogenous GPR143 in human melanoma cells, the amount of vector transfected was positively correlated with cell migration (Bai et al., 2014). This effect could be inhibited by siRNA-mediated GPR143 knockdown (Bai et al., 2014). GPR143 expression increased with progression towards metastasis (Fernandez et al., 2009; Bai et al., 2014). In addition, the study revealed that GPR143-induced melanoma cell metastasis activated the RAS/RAF/MEK/ERK signaling pathway (Bai et al., 2014). Bai et al. concluded from their findings, that GPR143 may serve as a metastasis-promoting gene in the progression of melanoma (Bai et al., 2014). Some melanosome-related proteins have been correlated with melanoma chemoresistance (Kottschade et al., 2016), for example the microphthalmia-associated transcription factor (MITF) was expressed at significantly higher levels in dacarbazine/temozolomide-resistant tumors when compared to sensitive tumors (Kottschade et al., 2016). Upregulation of GPR143 in chemoresistant melanoma may thus be due to upregulation of MITF, since MITF directly controls GPR143 expression (Vetrini et al., 2004; Kottschade et al., 2016).
Colorectal Cancer
Chromosome Xp22.2-22.3, where the OA1 gene is localized, is a colorectal cancer risk locus (Spatz et al., 2004; Benoît et al., 2007; McBride, 2016). Colorectal cancer is the second leading cause of cancer death worldwide with 881 000 estimated deaths in 2018 (Bray et al., 2018; Dolin et al., 2021). This type of cancer is highly associated with age (Ellison et al., 2018; Siegel et al., 2020; Dolin et al., 2021). Aside from an unhealthy lifestyle, colorectal cancer can also develop due to genetic mutations (Munteanu and Mastalier, 2014). Genome-wide association studies also identified GPR143 and its neighbor SHROOM2 as susceptibility genes for cancer (Dunlop et al., 2012; Closa et al., 2014; Chen Z. et al., 2019). Closa et al. hypothesized that since GPR143 and SHROOM2 may both play a role in retinal pigmentation and patients with familial adenomatous polyposis syndrome can also develop benign RPE lesions (known as congenital hypertrophy of retinal pigment epithelium lesions) mutations in the region of Xp22.2 may increase the risk for developing colorectal cancer (Díaz-Llopis and Menezo, 1988; Galiatsatos and Foulkes, 2006; Closa et al., 2014, https://rarediseases.org/rare-diseases/familial-adenomatous-polyposis/, accessed 4 January 2022).
GPR143 and Nicotine-Induced Behavior
Nicotine administration increases the release of L-DOPA in the nucleus accumbens of rats and promotes locomotion (walking, chewing etc.). The effects of nicotine can be suppressed by an L-DOPA antagonist, thus endogenous L-DOPA may play a role in nicotine-induced behavior (Goshima et al., 1996; Izawa et al., 2006). Since L-DOPA is a potential ligand for GPR143, Masukawa et al. investigated potential genetic association between GPR143 polymorphisms and smoking behavior in Japanese individuals (Masukawa et al., 2020). Their results pointed to rs6640499, a single-nucleotide polymorphism of GPR143, which was associated with traits of smoking behaviors such as number of cigarettes smoked per day (Masukawa et al., 2020). Surprisingly, in this study, Masukawa et al. found that nicotine reduced locomotion in WT mice (contrary to previous findings). GPR143 KO mice did not show a similar reduction. When investigating nicotine-induced reward related behavior, a significant difference was noted between WT and GPR143 KO mice at low nicotine doses, with reward behavior attenuated in the mutant mice (Masukawa et al., 2020).
GPR143 Interaction Partners
Melanosomal Proteins
The many hypotheses regarding GPR143 and its precise function may be due to its promiscuity in forming protein-protein-interactions (PPI) with different partners. GPR143 was initially shown to interact with melanocyte proteins, potentially while GPR143 is trafficked to melanosomes through endolysosomal/melanosomal pathways similar to other melanosomal proteins. (Winder et al., 1994). For instance the melanocyte protein melanoma antigen recognized by T-cells (MART-1), also known as melan-A (Kawakami et al., 1994), was shown to interact with GPR143 (Giordano et al., 2009). Giordano et al. showed, that inactivation of MART-1 would lead to a decreased stability of GPR143 and other defects in premelanosome biogenesis, suggesting that MART-1 acts as an escort for GPR143 at early stages of melanosome formation (Giordano et al., 2009).
De Filippo et al. GPR143 found that GPR143 interacts with tyrosinase, the rate-limiting enzyme of melanin synthesis (De Filippo et al., 2017b). The interaction may be required to effectively control melanosome maturation. Earlier in vivo studies had shown that KO of both GPR143 and tyrosinase would prevent macromelanosomes formation (Cortese et al., 2005).
GPR143 was also shown to bind tubulin in a study by Palmisano et al., where GPR143 knockout mice showed abnormal melanosome distribution in RPE and melanocytes (Palmisano et al., 2008). This defect was rescued when GPR143 was re-expressed following transfection suggesting that melanosomes require GPR143 for microtubule-mediated distribution from the perinuclear area to the cell periphery (Palmisano et al., 2008). Since tyrosinase would be expected to bind GPR143 in the lumen of the melanosome and tubulin in the intercellular space, GPR143 may interact with proteins/ligands from both membrane faces (Schiaffino and Tacchetti, 2005).
In GPR143 deficient cells, fewer but larger marcomelanosomes are observed (Sitaram and Marks, 2012). As the precise regulation of melanosome size is not fully understood, the role of master regulator of melanocyte differentiation, MITF was investigated in association with GPR143 (Falletta et al., 2014). It was reported that GPR143 is able to interact with MITF through a feedback loop, being both a regulator and target. GRP143 may also impact other genes regulated by MITF (Vetrini et al., 2004; Falletta et al., 2014). For example, the melanosome scaffold protein (PMEL) required for melanosome maturation, was functionally linked to GPR143. Loss of GPR143 function reduced both basal expression of MITF and α-melanocyte-stimulating hormone-dependent induction of MITF. Hence, expression of PMEL was also reduced (Falletta et al., 2014). The authors concluded that GPR143 modulates melanosome maturation by enhancing MITF expression and coordinating melansomes size and number in a quality control-manner (Falletta et al., 2014).
G Protein-Coupled Receptors
Masukawa et al. determined that α1b-adrenoceptor and GPR143 are able to form functional heteromers that modulate noradrenaline-mediated regulation of blood pressure through L-DOPA (Masukawa et al., 2017). In their study, mice were given an infusion of phenylephrine (an α1b-adrenoceptor agonist) that caused a transient increase in blood pressure in wildtype but not GPR143-mutant mice (Masukawa et al., 2017; Goshima et al., 2019a). Interaction was further confirmed by colocalization in FRET and in situ proximity ligation assays, furthermore, the binding affinity between the two receptors was enhanced in immunoprecipitation assays following pretreatment with L-DOPA (Masukawa et al., 2017) (see chapter 4.2. above).
We demonstrated that GPR143 forms functional dimers with D2R and D3R, which results in significant reduction of D2/3R response towards dopamine. GRP143 may exert its effect either by changing DR affinity for dopamine or by delaying the delivery of the DRs to the plasma membrane (Bueschbell et al., 2021). The link between the pigmentary system and dopaminergic signaling may be critical for optic tract development, since GPR143 function and tyrosinase activity could facilitate formation of an L-DOPA concentration gradient that allows for correct nerve projection during development (Chen et al., 2015; Chagraoui et al., 2019; Bueschbell et al., 2021).
GPR143 and its effect on DRs may play a role in the pathology of AMD due to their effect on dopamine in retinal neurons and RPE where L-DOPA is converted to dopamine (Figueroa and McKay, 2019).
Conclusion and Future Aspects
GPR143, first discovered as the product of the gene mutated in ocular albinism 1, is an enigmatic receptor that is unusual in many ways. It is expressed intracellularly and cannot be readily classified into a particular GPCR family. Neither the signaling pathways nor the exact functions of the protein have been defined, particularly with regard to its role in disease pathophysiology. There are limited pharmacological tools available to analyze GPR143 pharmacological and biological functions. The aim of our review therefore was to shine light on this unique receptor by collecting relevant information about GPR143, focusing not only on a specific function, but rather aiming to bring together all facets of the potentially diverse roles the protein may play. We highlight structural features which suggest GPR143 is a class A GPCR since it shares only few features with class B receptors, as well as the involvement of the receptor in various diseases. GPR143 is on one hand important for early development of the eye, causing ocular albinism type 1, if mutated, and on the other hand implicated in a variety of degenerative diseases, such as macular degeneration and Parkinsons disease and potentially even plays a role in susceptibility and progression of cancers. GPR143 is not a mainstream receptor in terms of drug development. Nevertheless, it is a prime example of an orphan receptor with therapeutic potential. Much more research is needed to fully understand the (patho)physiology of GPR143.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2022.873777/full#supplementary-material
References
1
AgasidM. T.SørensenL.UrnerL. H.YanJ.RobinsonC. V. (2021). The Effects of Sodium Ions on Ligand Binding and Conformational States of G Protein-Coupled Receptors-Insights from Mass Spectrometry. J. Am. Chem. Soc.143, 4085–4089. 10.1021/jacs.0c11837
2
AlexanderS. P.ChristopoulosA.DavenportA. P.KellyE.MarrionN. V.PetersJ. A. (2017). The Concise Guide to Pharmacology 2017/18: G Protein-Coupled Receptors. Br. J. Pharmacol.174Suppl. 1, S17–S129. 10.1111/bph.13878
3
AlexanderS. P. H.ChristopoulosA.DavenportA. P.KellyE.MathieA.PetersJ. A.et al (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G Protein-Coupled Receptors. Br. J. Pharmacol.176 (Suppl. 1), S21–S141. 10.1111/bph.14748
4
AlhadeffR.VorobyovI.YoonH. W.WarshelA. (2018). Exploring the Free-Energy Landscape of GPCR Activation. Proc. Natl. Acad. Sci. U. S. A.115, 10327–10332. 10.1073/pnas.1810316115
5
Alvarez-ArtimeA.Cernuda-CernudaR.Artime-NavedaF.CepasV.Gonzalez-MenendezP.Fernadez-VegaS.et al (2020). Melatonin-Induced Cytoskeleton Reorganization Leads to Inhibition of Melanoma Cancer Cell Proliferation. Int. J. Mol. Sci.21. 10.3390/ijms21020548
6
AngelT. E.ChanceM. R.PalczewskiK. (2009). Conserved Waters Mediate Structural and Functional Activation of Family A (Rhodopsin-like) G Protein-Coupled Receptors. Proc. Natl. Acad. Sci. U. S. A.106, 8555–8560. 10.1073/pnas.0903545106
7
ArimontM.van der WoudeM.LeursR.VischerH. F.de GraafC.NijmeijerS. (2019). Identification of Key Structural Motifs Involved in 7 Transmembrane Signaling of Adhesion GPCRs. ACS Pharmacol. Transl. Sci.2, 101–113. 10.1021/acsptsci.8b00051
8
AttwoodT. K.FindlayJ. B. (1994). Fingerprinting G-Protein-Coupled Receptors. Protein Eng.7, 195–203. 10.1093/protein/7.2.195
9
BaiJ.XieX.LeiY.AnG.HeL.LvX. (2014). Ocular Albinism Type 1-induced Melanoma Cell Migration Is Mediated through the RAS/RAF/MEK/ERK Signaling Pathway. Mol. Med. Rep.10, 491–495. 10.3892/mmr.2014.2154
10
BallesterosJ. A.JensenA. D.LiapakisG.RasmussenS. G.ShiL.GetherU.et al (2001). Activation of the Beta 2-adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6. J. Biol. Chem.276, 29171–29177. 10.1074/jbc.M103747200
11
BallesterosJ. A.WeinsteinH. (1995). “[19] Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure-Function Relations in G Protein-Coupled Receptors,” in Methods in Neurosciences. Editor SealfonS. C. (Academic Press), 366–428. 10.1016/S1043-9471(05)80049-7
12
BallesterosJ.KitanovicS.GuarnieriF.DaviesP.FrommeB. J.KonvickaK.et al (1998). Functional Microdomains in G-Protein-Coupled Receptors. The Conserved Arginine-Cage Motif in the Gonadotropin-Releasing Hormone Receptor. J. Biol. Chem.273, 10445–10453. 10.1074/jbc.273.17.10445
13
BassiM. T.SchiaffinoM. V.RenieriA.De NigrisF.GalliL.BruttiniM.et al (1995). Cloning of the Gene for Ocular Albinism Type 1 from the Distal Short Arm of the X Chromosome. Nat. Genet.10, 13–19. 10.1038/ng0595-13
14
BeliuG.AltrichterS.Guixà-GonzálezR.HembergerM.BrauerI.DahseA.-K.et al (2021). Tethered Agonist Exposure in Intact Adhesion/class B2 GPCRs through Intrinsic Structural Flexibility of the GAIN Domain. Mol. Cel81, 905–921. 10.1016/j.molcel.2020.12.042
15
BenoîtM.-H.HudsonT. J.MaireG.SquireJ. A.ArcandS. L.ProvencherD.et al (2007). Global Analysis of Chromosome X Gene Expression in Primary Cultures of normal Ovarian Surface Epithelial Cells and Epithelial Ovarian Cancer Cell Lines. Int. J. Oncol.30, 5–17. 10.3892/ijo.30.1.5
16
BergeL. A. M.AndreassenB. K.StenehjemJ. S.HeirT.FuruK.JuzenieneA.et al (2020). Use of Antidepressants and Risk of Cutaneous Melanoma: A Prospective Registry-Based Case-Control Study. Clin. Epidemiol.12, 193–202. 10.2147/CLEP.S241249
17
BordenE. S.AdamsA. C.BuetowK. H.WilsonM. A.BaumanJ. E.Curiel-LewandrowskiC.et al (2021). Shared Gene Expression and Immune Pathway Changes Associated with Progression from Nevi to Melanoma. Cancers14. 10.3390/cancers14010003
18
BourneR. R. A.StevensG. A.WhiteR. A.SmithJ. L.FlaxmanS. R.PriceH.et al (2013). Causes of Vision Loss Worldwide, 1990-2010: a Systematic Analysis. Lancet Glob. Health1, e339–49. 10.1016/S2214-109X(13)70113-X
19
BrayF.FerlayJ.SoerjomataramI.SiegelR. L.TorreL. A.JemalA. (2018). Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin.68, 394–424. 10.3322/caac.21492
20
BrilliantM. H.VaziriK.ConnorT. B.JrSchwartzS. G.CarrollJ. J.McCartyC. A.et al (2016). Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-Related Macular Degeneration. Am. J. Med.129, 292–298. 10.1016/j.amjmed.2015.10.015
21
BueschbellB.MangaP.PennerE.SchiedelA. C. (2021). Evidence for Protein-Protein Interaction between Dopamine Receptors and the G Protein-Coupled Receptor 143. Int. J. Mol. Sci.22. 10.3390/ijms22158328
22
CaltabianoG.GonzalezA.CordomíA.CampilloM.PardoL. (2013). The Role of Hydrophobic Amino Acids in the Structure and Function of the Rhodopsin Family of G Protein-Coupled Receptors. Methods Enzymol.520, 99–115. 10.1016/B978-0-12-391861-1.00005-8
23
ChagraouiA.BoulainM.JuvinL.AnouarY.BarrièreG.DeurwaerdèreP. D. (2019). L-DOPA in Parkinson’s Disease: Looking at the “False” Neurotransmitters and Their Meaning. Int. J. Mol. Sci.21. 10.3390/ijms21010294
24
ChenS.LuM.LiuD.YangL.YiC.MaL.et al (2019a). Human Substance P Receptor Binding Mode of the Antagonist Drug Aprepitant by NMR and Crystallography. Nat. Commun.10, 638. 10.1038/s41467-019-08568-5
25
ChenT.HuY.LinX.HuangX.LiuB.LeungP.et al (2015). Dopamine Signaling Regulates the Projection Patterns in the Mouse Chiasm. Brain Res.1625, 324–336. 10.1016/j.brainres.2015.08.026
26
ChenZ.WenW.Beeghly-FadielA.ShuX.-O.Díez-ObreroV.LongJ.et al (2019b). Identifying Putative Susceptibility Genes and Evaluating Their Associations with Somatic Mutations in Human Cancers. Am. J. Hum. Genet.105, 477–492. 10.1016/j.ajhg.2019.07.006
27
CherepakhinO. S.ArgenyiZ. B.MoshiriA. S. (2021). Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis. Cancers14. 10.3390/cancers14010123
28
ClosaA.CorderoD.Sanz-PamplonaR.SoléX.Crous-BouM.Paré-BrunetL.et al (2014). Identification of Candidate Susceptibility Genes for Colorectal Cancer through eQTL Analysis. Carcinogenesis35, 2039–2046. 10.1093/carcin/bgu092
29
ColemanH. R.ChanC.-C.FerrisF. L.3rdChewE. Y. (2008). Age-related Macular Degeneration. Lancet372, 1835–1845. 10.1016/S0140-6736(08)61759-6
30
ColemanJ. L. J.NgoT.SmithN. J. (2017). The G Protein-Coupled Receptor N-Terminus and Receptor Signalling: N-Tering a new era. Cell. Signal.33, 1–9. 10.1016/j.cellsig.2017.02.004
31
CorteseK.GiordanoF.SuraceE. M.VenturiC.BallabioA.TacchettiC.et al (2005). The Ocular Albinism Type 1 (OA1) Gene Controls Melanosome Maturation and Size. Invest. Ophthalmol. Vis. Sci.46, 4358–4364. 10.1167/iovs.05-0834
32
CreelD. J.SummersC. G.KingR. A. (1990). Visual Anomalies Associated with Albinism. Ophthalmic Paediatr. Genet.11, 193–200. 10.3109/13816819009020979
33
DaubnerS. C.LeT.WangS. (2011). Tyrosine Hydroxylase and Regulation of Dopamine Synthesis. Arch. Biochem. Biophys.508, 1–12. 10.1016/j.abb.2010.12.017
34
De FilippoE.MangaP.SchiedelA. C. (2017c). Author Response: Comment on "Identification of Novel G Protein–Coupled Receptor 143 Ligands as Pharmacologic Tools for Investigating X-Linked Ocular Albinism. Invest. Ophthalmol. Vis. Sci.58, 4735–4736. 10.1167/iovs.17-22810
35
De FilippoE.MangaP.SchiedelA. C. (2017a). Identification of Novel G Protein–Coupled Receptor 143 Ligands as Pharmacologic Tools for Investigating X-Linked Ocular Albinism. Invest. Ophthalmol. Vis. Sci.58, 3118–3126. 10.1167/iovs.16-21128
36
De FilippoE.SchiedelA. C.MangaP. (2017b). Interaction between G Protein-Coupled Receptor 143 and Tyrosinase: Implications for Understanding Ocular Albinism Type 1. J. Invest. Dermatol.137, 457–465. 10.1016/j.jid.2016.09.022
37
DeweyR. B.JrMaraganoreD. M. (1994). Isolated Eyelid-Opening Apraxia: Report of a New Levodopa-Responsive Syndrome. Neurology44, 1752–1754. 10.1212/wnl.44.9.1752
38
Díaz-LlopisM.MenezoJ. L. (1988). Congenital Hypertrophy of the Retinal Pigment Epithelium in Familial Adenomatous Polyposis. Arch. Ophthalmol.106, 412–413. 10.1001/archopht.1988.01060130438037
39
D’MelloS. A. N.FinlayG. J.BaguleyB. C.Askarian-AmiriM. E. (2016). Signaling Pathways in Melanogenesis. Int. J. Mol. Sci.17. 10.3390/ijms17071144
40
DolinT. G.ChristensenI. J.JohansenA. Z.NielsenH. J.JakobsenH. L.KleinM. F.et al (2021). Pre- and Perioperative Inflammatory Biomarkers in Older Patients Resected for Localized Colorectal Cancer: Associations with Complications and Prognosis. Cancers14. 10.3390/cancers14010161
41
DubocovichM. L.LangerS. Z. (1980). Dopamine and Alpha Adrenoceptor Agonists Inhibit Neurotransmission in the Cat Spleen through Different Presynaptic Receptors. J. Pharmacol. Exp. Ther.212, 144–152. Available at: https://www.ncbi.nlm.nih.gov/pubmed/6101339.
42
DunlopM. G.DobbinsS. E.FarringtonS. M.JonesA. M.PallesC.WhiffinN.et al (2012). Common Variation Near CDKN1A, POLD3 and SHROOM2 Influences Colorectal Cancer Risk. Nat. Genet.44, 770–776. 10.1038/ng.2293
43
EddyM. T.LeeM.-Y.GaoZ.-G.WhiteK. L.DidenkoT.HorstR.et al (2018). Allosteric Coupling of Drug Binding and Intracellular Signaling in the A2A Adenosine Receptor. Cell172, 68–80. 10.1016/j.cell.2017.12.004
44
EllisonE. C.PawlikT. M.WayD. P.SatianiB.WilliamsT. E. (2018). The Impact of the Aging Population and Incidence of Cancer on Future Projections of General Surgical Workforce Needs. Surgery163, 553–559. 10.1016/j.surg.2017.09.035
45
FalkT.CongroveN. R.ZhangS.McCourtA. D.ShermanS. J.McKayB. S. (20122012). PEDF and VEGF-A Output from Human Retinal Pigment Epithelial Cells Grown on Novel Microcarriers. J. Biomed. Biotechnol., 278932. 10.1155/2012/278932
46
FalkT.GonzalezR. T.ShermanS. J. (2010). The Yin and Yang of VEGF and PEDF: Multifaceted Neurotrophic Factors and Their Potential in the Treatment of Parkinson’s Disease. Int. J. Mol. Sci.11, 2875–2900. 10.3390/ijms11082875
47
FallettaP.BagnatoP.BonoM.MonticoneM.SchiaffinoM. V.BennettD. C.et al (2014). Melanosome-autonomous Regulation of Size and Number: the OA1 Receptor Sustains PMEL Expression. Pigment Cel Melanoma Res27, 565–579. 10.1111/pcmr.12239
48
FallsH. F. (1951). Sex-linked Ocular Albinism Displaying Typical Fundus Changes in the Female Heterozygote. Am. J. Ophthalmol.34, 41–50. 10.1016/0002-9394(51)90007-4
49
FengX.AmbiaJ.ChenK.-Y. M.YoungM.BarthP. (2017). Computational Design of Ligand-Binding Membrane Receptors with High Selectivity. Nat. Chem. Biol.13, 715–723. 10.1038/nchembio.2371
50
FerlayJ.ColombetM.SoerjomataramI.ParkinD. M.PiñerosM.ZnaorA.et al (2021). Cancer Statistics for the Year 2020: An Overview. Int. J. Cancer. 10.1002/ijc.33588
51
FernandezL. P.MilneR. L.PitaG.FloristanU.SendagortaE.FeitoM.et al (2009). Pigmentation-related Genes and Their Implication in Malignant Melanoma Susceptibility. Exp. Dermatol.18, 634–642. 10.1111/j.1600-0625.2009.00846.x
52
FigueroaA. G.McKayB. S. (2019). GPR143 Signaling and Retinal Degeneration. Adv. Exp. Med. Biol.1185, 15–19. 10.1007/978-3-030-27378-1_3
53
FilipekS. (2019). Molecular Switches in GPCRs. Curr. Opin. Struct. Biol.55, 114–120. 10.1016/j.sbi.2019.03.017
54
FinstererJ. (2003). Ptosis: Causes, Presentation, and Management. Aesthet. Plast. Surg.27, 193–204. 10.1007/s00266-003-0127-5
55
FredrikssonR.LagerströmM. C.LundinL.-G.SchiöthH. B. (2003). The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints. Mol. Pharmacol.63, 1256–1272. 10.1124/mol.63.6.1256
56
FritzeO.FilipekS.KuksaV.PalczewskiK.HofmannK. P.ErnstO. P. (2003). Role of the Conserved NPxxY(x)5,6F Motif in the Rhodopsin Ground State and during Activation. Proc. Natl. Acad. Sci. U. S. A.100, 2290–2295. 10.1073/pnas.0435715100
57
FukudaN.NaitoS.MasukawaD.KanedaM.MiyamotoH.AbeT.et al (2015). Expression of Ocular Albinism 1 (OA1), 3, 4- Dihydroxy- L-Phenylalanine (DOPA) Receptor, in Both Neuronal and Non-neuronal Organs. Brain Res.1602, 62–74. 10.1016/j.brainres.2015.01.020
58
GaliatsatosP.FoulkesW. D. (2006). Familial Adenomatous Polyposis. Am. J. Gastroenterol.101, 385–398. 10.1111/j.1572-0241.2006.00375.x
59
GarnerA.JayB. S. (1980). Macromelanosomes in X-Linked Ocular Albinism. Histopathology4, 243–254. 10.1111/j.1365-2559.1980.tb02919.x
60
GeerlingJ. C.LoewyA. D. (2006). Aldosterone-sensitive Neurons in the Nucleus of the Solitary Tract: Efferent Projections. J. Comp. Neurol.497, 223–250. 10.1002/cne.20993
61
GhoshA.SonavaneU.AndhirkaS. K.AradhyamG. K.JoshiR. (2012). Structural Insights into Human GPCR Protein OA1: a Computational Perspective. J. Mol. Model.18, 2117–2133. 10.1007/s00894-011-1228-8
62
GiladiN.McMahonD.PrzedborskiS.FlasterE.GuilloryS.KosticV.et al (1992). Motor Blocks in Parkinson’s Disease. Neurology42, 333–339. 10.1212/wnl.42.2.333
63
GilchrestB. A.EllerM. S.GellerA. C.YaarM. (1999). The Pathogenesis of Melanoma Induced by Ultraviolet Radiation. N. Engl. J. Med.340, 1341–1348. 10.1056/NEJM199904293401707
64
GiordanoF.BonettiC.SuraceE. M.MarigoV.RaposoG. (2009). The Ocular Albinism Type 1 (OA1) G-Protein-Coupled Receptor Functions with MART-1 at Early Stages of Melanogenesis to Control Melanosome Identity and Composition. Hum. Mol. Genet.18, 4530–4545. 10.1093/hmg/ddp415
65
GiordanoF.SimoesS.RaposoG. (2011). The Ocular Albinism Type 1 (OA1) GPCR Is Ubiquitinated and its Traffic Requires Endosomal Sorting Complex Responsible for Transport (ESCRT) Function. Proc. Natl. Acad. Sci. U. S. A.108, 11906–11911. 10.1073/pnas.1103381108
66
GohlaA.KlementK.PiekorzR. P.PexaK.vom DahlS.SpicherK.et al (2007). An Obligatory Requirement for the Heterotrimeric G Protein Gi3 in the Antiautophagic Action of Insulin in the Liver. Proc. Natl. Acad. Sci. U. S. A.104, 3003–3008. 10.1073/pnas.0611434104
67
GoshimaY.KuboT.MisuY. (1986). Biphasic Actions of L-DOPA on the Release of Endogenous Noradrenaline and Dopamine from Rat Hypothalamic Slices. Br. J. Pharmacol.89, 229–234. 10.1111/j.1476-5381.1986.tb11139.x
68
GoshimaY.KuboT.MisuY. (1988). Transmitter-like Release of Endogenous 3,4-dihydroxyphenylalanine from Rat Striatal Slices. J. Neurochem.50, 1725–1730. 10.1111/j.1471-4159.1988.tb02470.x
69
GoshimaY.MasukawaD.KasaharaY.HashimotoT.AladeokinA. C. (2019a). l-DOPA and its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease. Front. Pharmacol.10, 1119. 10.3389/fphar.2019.01119
70
GoshimaY.MiyamaeT.NakamuraS.MikiK.KosakaK.MisuY. (1996). Ventral Tegmental Injection of Nicotine Induces Locomotor Activity and L-DOPA Release from Nucleus Accumbens. Eur. J. Pharmacol.309, 229–233. 10.1016/0014-2999(96)00458-x
71
GoshimaY.NakamuraF.MasukawaD.ChenS.KogaM. (2014). Cardiovascular Actions of DOPA Mediated by the Gene Product of Ocular Albinism 1. J. Pharmacol. Sci.126, 14–20. 10.1254/jphs.14r03cr
72
GoshimaY.WatanabeS.SekiE.KogaM.MasukawaD.NakamuraF.et al (2019b). Immunoreactivity of a G Protein-Coupled L-DOPA Receptor GPR143, in Lewy Bodies. Neurosci. Res.148, 49–53. 10.1016/j.neures.2018.12.004
73
HamannJ.AustG.AraçD.EngelF. B.FormstoneC.FredrikssonR.et al (2015). International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G Protein-Coupled Receptors. Pharmacol. Rev.67, 338–367. 10.1124/pr.114.009647
74
HanR.WangX.WangD.WangL.YuanZ.YingM.et al (2015). GPR143 Gene Mutations in Five Chinese Families with X-Linked Congenital Nystagmus. Sci. Rep.5, 12031. 10.1038/srep12031
75
HardingS. D.SharmanJ. L.FaccendaE.SouthanC.PawsonA. J.IrelandS.et al (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: Updates and Expansion to Encompass the New Guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res.46, D1091–D1106. 10.1093/nar/gkx1121
76
HauserA. S.AttwoodM. M.Rask-AndersenM.SchiöthH. B.GloriamD. E. (2017). Trends in GPCR Drug Discovery: New Agents, Targets and Indications. Nat. Rev. Drug Discov.16, 829–842. 10.1038/nrd.2017.178
77
HilgerD. (2021). The Role of Structural Dynamics in GPCR-Mediated Signaling. FEBS J.288, 2461–2489. 10.1111/febs.15841
78
HiroshimaY.MiyamotoH.NakamuraF.MasukawaD.YamamotoT.MuraokaH.et al (2014). The Protein Ocular Albinism 1 Is the Orphan GPCR GPR143 and Mediates Depressor and Bradycardic Responses to DOPA in the Nucleus Tractus Solitarii. Br. J. Pharmacol.171, 403–414. 10.1111/bph.12459
79
HoareS. R. J. (2005). Mechanisms of Peptide and Nonpeptide Ligand Binding to Class B G-Protein-Coupled Receptors. Drug Discov. Today10, 417–427. 10.1016/S1359-6446(05)03370-2
80
HofmannK. P.ScheererP.HildebrandP. W.ChoeH.-W.ParkJ. H.HeckM.et al (2009). A G Protein-Coupled Receptor at Work: the Rhodopsin Model. Trends Biochem. Sci.34, 540–552. 10.1016/j.tibs.2009.07.005
81
HolstB.NygaardR.Valentin-HansenL.BachA.EngelstoftM. S.PetersenP. S.et al (2010). A Conserved Aromatic Lock for the Tryptophan Rotameric Switch in TM-VI of Seven-Transmembrane Receptors. J. Biol. Chem.285, 3973–3985. 10.1074/jbc.M109.064725
82
HornykiewiczO. (2006). The Discovery of Dopamine Deficiency in the Parkinsonian Brain. J. Neural Transm. Suppl., 9–15. 10.1007/978-3-211-45295-0_3
83
HuG.-M.MaiT.-L.ChenC.-M. (2017). Visualizing the GPCR Network: Classification and Evolution. Sci. Rep.7, 15495. 10.1038/s41598-017-15707-9
84
InnamoratiG.PiccirilloR.BagnatoP.PalmisanoI.SchiaffinoM. V. (2006). The Melanosomal/lysosomal Protein OA1 Has Properties of a G Protein-Coupled Receptor. Pigment Cel Res19, 125–135. 10.1111/j.1600-0749.2006.00292.x
85
IsbergV.de GraafC.BortolatoA.CherezovV.KatritchV.MarshallF. H.et al (2015). Generic GPCR Residue Numbers - Aligning Topology Maps while Minding the Gaps. Trends Pharmacol. Sci.36, 22–31. 10.1016/j.tips.2014.11.001
86
IsbergV.MordalskiS.MunkC.RatajK.HarpsøeK.HauserA. S.et al (2016). GPCRdb: an Information System for G Protein-Coupled Receptors. Nucleic Acids Res.44, D356–D364. 10.1093/nar/gkv1178
87
IshchenkoA.WackerD.KapoorM.ZhangA.HanG. W.BasuS.et al (2017). Structural Insights into the Extracellular Recognition of the Human Serotonin 2B Receptor by an Antibody. Proc. Natl. Acad. Sci. U. S. A.114, 8223–8228. 10.1073/pnas.1700891114
88
IzawaJ.-I.YamanashiK.AsakuraT.MisuY.GoshimaY. (2006). Differential Effects of Methamphetamine and Cocaine on Behavior and Extracellular Levels of Dopamine and 3,4-dihydroxyphenylalanine in the Nucleus Accumbens of Conscious Rats. Eur. J. Pharmacol.549, 84–90. 10.1016/j.ejphar.2006.08.031
89
JabeenA.RanganathanS. (2019). Applications of Machine Learning in GPCR Bioactive Ligand Discovery. Curr. Opin. Struct. Biol.55, 66–76. 10.1016/j.sbi.2019.03.022
90
JacobsonK. A.CostanziS.PaolettaS. (2014). Computational Studies to Predict or Explain G Protein Coupled Receptor Polypharmacology. Trends Pharmacol. Sci.35, 658–663. 10.1016/j.tips.2014.10.009
91
JiangM.PandeyS.TranV. T.FongH. K. (1991). Guanine Nucleotide-Binding Regulatory Proteins in Retinal Pigment Epithelial Cells. Proc. Natl. Acad. Sci. U. S. A.88, 3907–3911. 10.1073/pnas.88.9.3907
92
KaiserA.HempelC.WankaL.SchubertM.HammH. E.Beck-SickingerA. G. (2018). G Protein Preassembly Rescues Efficacy of W6.48 Toggle Mutations in Neuropeptide Y2 Receptor. Mol. Pharmacol.93, 387–401. 10.1124/mol.117.110544
93
KarageorgosV.VenihakiM.SakellarisS.PardalosM.KontakisG.MatsoukasM.-T.et al (2018). Current Understanding of the Structure and Function of Family B GPCRs to Design Novel Drugs. Hormones17, 45–59. 10.1007/s42000-018-0009-5
94
KarczewskiK. J.FrancioliL. C.TiaoG.CummingsB. B.AlföldiJ.WangQ.et al (2020). The Mutational Constraint Spectrum Quantified from Variation in 141,456 Humans. Nature581, 434–443. 10.1038/s41586-020-2308-7
95
KasaharaY.MasukawaD.KobayashiK.YamasakiM.WatanabeM.GoshimaY. (2022). L-DOPA-induced Neurogenesis in the Hippocampus Is Mediated through GPR143, a Distinct Mechanism of Dopamine. Stem Cells. 10.1093/stmcls/sxab013
96
KatoH. E.ZhangY.HuH.SuomivuoriC.-M.KadjiF. M. N.AokiJ.et al (2019). Conformational Transitions of a Neurotensin Receptor 1-Gi1 Complex. Nature572, 80–85. 10.1038/s41586-019-1337-6
97
KatritchV.FenaltiG.AbolaE. E.RothB. L.CherezovV.StevensR. C. (2014). Allosteric Sodium in Class A GPCR Signaling. Trends Biochem. Sci.39, 233–244. 10.1016/j.tibs.2014.03.002
98
KawakamiY.EliyahuS.DelgadoC. H.RobbinsP. F.RivoltiniL.TopalianS. L.et al (1994). Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor. Proc. Natl. Acad. Sci. U. S. A.91, 3515–3519. 10.1073/pnas.91.9.3515
99
KimS. J.SungJ. Y.UmJ. W.HattoriN.MizunoY.TanakaK.et al (2003). Parkin Cleaves Intracellular Alpha-Synuclein Inclusions via the Activation of Calpain. J. Biol. Chem.278, 41890–41899. 10.1074/jbc.M306017200
100
KohliJ. D. (1990). Peripheral Dopamine Receptors. Am. J. Hypertens.3, 25S–28S. 10.1093/ajh/3.6.25s
101
KolakowskiL. F.Jr (1994). GCRDb: a G-Protein-Coupled Receptor Database. Receptors Channels2, 1–7. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8081729.
102
KooistraA. J.MordalskiS.Pándy-SzekeresG.EsguerraM.MamyrbekovA.MunkC.et al (2021). GPCRdb in 2021: Integrating GPCR Sequence, Structure and Function. Nucleic Acids Res.49, D335–D343. 10.1093/nar/gkaa1080
103
KottschadeL. A.McWilliamsR. R.MarkovicS. N.BlockM. S.Villasboas BisnetoJ.PhamA. Q.et al (2016). The Use of Pembrolizumab for the Treatment of Metastatic Uveal Melanoma. Melanoma Res.26, 300–303. 10.1097/CMR.0000000000000242
104
KozarI.MargueC.RothengatterS.HaanC.KreisS. (2019). Many Ways to Resistance: How Melanoma Cells Evade Targeted Therapies. Biochim. Biophys. Acta Rev. Cancer1871, 313–322. 10.1016/j.bbcan.2019.02.002
105
KrissA.Russell-EggittI.HarrisC. M.LloydI. C.TaylorD. (1992). Aspects of Albinism. Ophthalmic Paediatr. Genet.13, 89–100. 10.3109/13816819209087609
106
KuboT.YueJ. L.GoshimaY.NakamuraS.MisuY. (1992). Evidence for L-Dopa Systems Responsible for Cardiovascular Control in the Nucleus Tractus Solitarii of the Rat. Neurosci. Lett.140, 153–156. 10.1016/0304-3940(92)90090-t
107
LangG. E.RottH. D.PfeifferR. A. (1990). X-linked Ocular Albinism. Characteristic Pattern of Affection in Female Carriers. Ophthalmic Paediatr. Genet.11, 265–271. 10.3109/13816819009015712
108
LatekD.PasznikP.CarlomagnoT.FilipekS. (2013). Towards Improved Quality of GPCR Models by Usage of Multiple Templates and Profile-Profile Comparison. PLoS One8, e56742. 10.1371/journal.pone.0056742
109
LiJ.ZhangZ.LiG. (2011). Patient Outcome Prediction Using Multiple Biomarkers in Human Melanoma: A Clinicopathological Study of 118 Cases. Exp. Ther. Med.2, 131–135. 10.3892/etm.2010.169
110
LimL. S.MitchellP.SeddonJ. M.HolzF. G.WongT. Y. (2012). Age-related Macular Degeneration. Lancet379, 1728–1738. 10.1016/S0140-6736(12)60282-7
111
LiuJ. Y.RenX.YangX.GuoT.YaoQ.LiL.et al (2007). Identification of a Novel GPR143 Mutation in a Large Chinese Family with Congenital Nystagmus as the Most Prominent and Consistent Manifestation. J. Hum. Genet.52, 565–570. 10.1007/s10038-007-0152-3
112
LiuW.ChunE.ThompsonA. A.ChubukovP.XuF.KatritchV.et al (2012). Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions. Science337, 232–236. 10.1126/science.1219218
113
LopezV. M.DecaturC. L.StamerW. D.LynchR. M.McKayB. S. (2008). L-DOPA Is an Endogenous Ligand for OA1. Plos Biol.6, e236. 10.1371/journal.pbio.0060236
114
MaoX.ChenM.YuY.LiuQ.YuanS.FanW. (2021). Identification of a Novel GPR143 Mutation in a Large Chinese Family with Isolated Foveal Hypoplasia. BMC Ophthalmol.21, 156. 10.1186/s12886-021-01905-7
115
MartinezD.KlineD. D. (2021). The Role of Astrocytes in the Nucleus Tractus Solitarii in Maintaining central Control of Autonomic Function. Am. J. Physiol. Regul. Integr. Comp. Physiol.320, R418–R424. 10.1152/ajpregu.00254.2020
116
MasukawaD.KogaM.SezakiA.NakaoY.KamikuboY.HashimotoT.et al (2017). L-DOPA Sensitizes Vasomotor Tone by Modulating the Vascular Alpha1-Adrenergic Receptor. JCI Insight2. 10.1172/jci.insight.90903
117
MasukawaD.NakamuraF.KogaM.KamiyaM.ChenS.YamashitaN.et al (2014). Localization of Ocular Albinism-1 Gene Product GPR143 in the Rat central Nervous System. Neurosci. Res.88, 49–57. 10.1016/j.neures.2014.07.008
118
MasukawaD.NishizawaD.KanaiK.KitamuraS.KasaharaY.HashimotoT.et al (2020). Genetic Associations of Single Nucleotide Polymorphisms in the L-DOPA Receptor (GPR143) Gene with Severity of Nicotine Dependence in Japanese Individuals, and Attenuation of Nicotine Reinforcement in Gpr143 Gene-Deficient Mice. J. Pharmacol. Sci.144, 89–93. 10.1016/j.jphs.2020.07.003
119
McBrideA. N. (2016). Development of a Novel Mouse Model for the Colorectal Cancer Risk Locus at Xp22.2. Available at: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.735700 (Accessed February 8, 2022).
120
McKayB. S.LynchR. M.StamerW. D. (2017). Comment on ‘‘Identification of Novel G Protein–Coupled Receptor 143 Ligands as Pharmacologic Tools for Investigating X-Linked Ocular albinism.’’ Invest. Ophthalmol. Vis. Sci.58, 4733–4734. 10.1167/iovs.17-22660
121
McKayB. S.CongroveN. R.JohnsonA. A.DismukeW. M.BowenT. J.StamerW. D. (2013). A Role for Myocilin in Receptor-Mediated Endocytosis. PLoS One8, e82301. 10.1371/journal.pone.0082301
122
Michael ConnP. (2008). Neuroscience in Medicine. Springer Science & Business Media. Available at: https://play.google.com/store/books/details?id=sor_roKluskC.
123
MichaudV.Defoort-DhellemmesS.DrumareI.PennamenP.PlaisantC.LasseauxE.et al (2019). Clinical and Molecular Findings of FRMD7 Related Congenital Nystagmus as Adifferential Diagnosis of Ocular Albinism. Ophthalmic Genet.40, 161–164. 10.1080/13816810.2019.1592201
124
MitchellP.LiewG.GopinathB.WongT. Y. (2018). Age-related Macular Degeneration. Lancet392, 1147–1159. 10.1016/S0140-6736(18)31550-2
125
MombaertsP. (2004). Genes and Ligands for Odorant, Vomeronasal and Taste Receptors. Nat. Rev. Neurosci.5, 263–278. 10.1038/nrn1365
126
MonfaredR. V.AlhassenW.TruongT. M.GonzalesM. A. M.VachirakorntongV.ChenS.et al (2021). Transcriptome Profiling of Dysregulated GPCRs Reveals Overlapping Patterns across Psychiatric Disorders and Age-Disease Interactions. Cells10. 10.3390/cells10112967
127
MoreiraI. S.ShiL.FreybergZ.EricksenS. S.WeinsteinH.JavitchJ. A. (2010). “Structural Basis of Dopamine Receptor Activation,” in The Dopamine Receptors. Editor NeveK. A. (Totowa, NJ: Humana Press), 47–73. 10.1007/978-1-60327-333-6_3
128
MoreiraI. S. (2014). Structural Features of the G-Protein/GPCR Interactions. Biochim. Biophys. Acta1840, 16–33. 10.1016/j.bbagen.2013.08.027
129
MoustafaA. A.ChakravarthyS.PhillipsJ. R.GuptaA.KeriS.PolnerB.et al (2016). Motor Symptoms in Parkinson’s Disease: A Unified Framework. Neurosci. Biobehav. Rev.68, 727–740. 10.1016/j.neubiorev.2016.07.010
130
MunteanuI.MastalierB. (2014). Genetics of Colorectal Cancer. J. Med. Life7, 507–511. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25713610.
131
NakamuraS.GoshimaY.YueJ. L.MisuY. (1992). Transmitter-like Basal and K(+)-evoked Release of 3,4-dihydroxyphenylalanine from the Striatum in Conscious Rats Studied by Microdialysis. J. Neurochem.58, 270–275. 10.1111/j.1471-4159.1992.tb09306.x
132
NakanoM.KogaM.HashimotoT.MatsushitaN.MasukawaD.MizunoY.et al (2022). Right Ventricular Overloading Is Attenuated in Monocrotaline-Induced Pulmonary Hypertension Model Rats with a Disrupted Gpr143 Gene, the Gene that Encodes the 3,4-L-Dihydroxyphenyalanine (L-DOPA) Receptor. J. Pharmacol. Sci.148, 214–220. 10.1016/j.jphs.2021.11.008
133
NazarkoO.KibromA.WinklerJ.LeonK.StovekenH.SalzmanG.et al (2018). A Comprehensive Mutagenesis Screen of the Adhesion GPCR Latrophilin-1/ADGRL1. iScience3, 264–278. 10.1016/j.isci.2018.04.019
134
NijmeijerS.WolfS.ErnstO. P.de GraafC. (2016). “7TM Domain Structure of Adhesion GPCRs,” in Adhesion G Protein-Coupled Receptors: Molecular, Physiological and Pharmacological Principles in Health and Disease. Editors Langenhan.T.SchönebergT. (Cham: Springer International Publishing), 43–66. 10.1007/978-3-319-41523-9_3
135
NordströmK. J. V.LagerströmM. C.WallérL. M. J.FredrikssonR.SchiöthH. B. (2009). The Secretin GPCRs Descended from the Family of Adhesion GPCRs. Mol. Biol. Evol.26, 71–84. 10.1093/molbev/msn228
136
NygaardR.FrimurerT. M.HolstB.RosenkildeM. M.SchwartzT. W. (2009). Ligand Binding and Micro-switches in 7TM Receptor Structures. Trends Pharmacol. Sci.30, 249–259. 10.1016/j.tips.2009.02.006
137
O’CallaghanT. (2011). Introduction: The Prevention Agenda. Nature471, S2–S4. 10.1038/471S2a
138
OdoemelamC. S.PercivalB.WallisH.ChangM.-W.AhmadZ.ScholeyD.et al (2020). G-protein Coupled Receptors: Structure and Function in Drug Discovery. RSC Adv.10, 36337–36348. 10.1039/D0RA08003A
139
O’DonnellF. E.JrHambrickG. W.JrGreenW. R.IliffW. J.StoneD. L. (1976). X-linked Ocular Albinism. An Oculocutaneous Macromelanosomal Disorder. Arch. Ophthalmol.94, 1883–1892. 10.1001/archopht.1976.03910040593001
140
O’DonnellF. E. (1978). X-linked Ocular Albinism in Blacks. Arch. Ophthalmol.96, 1189. 10.1001/archopht.1978.03910060023005
141
OguniM.ShinoharaH.AsanoT.KatoK.SetogawaT. (1996). Ontogeny of GTP-Binding Proteins, Gi and G(o), in Rat Retina. Histochem. Cel Biol.106, 235–240. 10.1007/BF02484406
142
OrlowS. J. (1995). Melanosomes Are Specialized Members of the Lysosomal Lineage of Organelles. J. Invest. Dermatol.105, 3–7. 10.1111/1523-1747.ep12312291
143
PalK.MelcherK.XuH. E. (2012). Structure and Mechanism for Recognition of Peptide Hormones by Class B G-Protein-Coupled Receptors. Acta Pharmacol. Sin.33, 300–311. 10.1038/aps.2011.170
144
PalmisanoI.BagnatoP.PalmigianoA.InnamoratiG.RotondoG.AltimareD.et al (2008). The Ocular Albinism Type 1 Protein, an Intracellular G Protein-Coupled Receptor, Regulates Melanosome Transport in Pigment Cells. Hum. Mol. Genet.17, 3487–3501. 10.1093/hmg/ddn241
145
PanJ.-X.DingK.WangC.-Y. (2012). Niclosamide, an Old Antihelminthic Agent, Demonstrates Antitumor Activity by Blocking Multiple Signaling Pathways of Cancer Stem Cells. Chin. J. Cancer31, 178–184. 10.5732/cjc.011.10290
146
PandeyR. S.Wilson SayresM. A.AzadR. K. (2013). Detecting Evolutionary Strata on the Human X Chromosome in the Absence of Gametologous Y-Linked Sequences. Genome Biol. Evol.5, 1863–1871. 10.1093/gbe/evt139
147
Pándy-SzekeresG.MunkC.TsonkovT. M.MordalskiS.HarpsøeK.HauserA. S.et al (2018). GPCRdb in 2018: Adding GPCR Structure Models and Ligands. Nucleic Acids Res.46, D440–D446. 10.1093/nar/gkx1109
148
ParthierC.Reedtz-RungeS.RudolphR.StubbsM. T. (2009). Passing the Baton in Class B GPCRs: Peptide Hormone Activation via helix Induction?Trends Biochem. Sci.34, 303–310. 10.1016/j.tibs.2009.02.004
149
PeetersM. C.MosI.LenselinkE. B.LucchesiM.IJzermanA. P.SchwartzT. W. (2016). Getting from A to B-Exploring the Activation Motifs of the Class B Adhesion G Protein-Coupled Receptor Subfamily G Member 4/GPR112. FASEB J.30, 1836–1848. 10.1096/fj.201500110
150
PiccirilloR.PalmisanoI.InnamoratiG.BagnatoP.AltimareD.SchiaffinoM. V. (2006). An Unconventional Dileucine-Based Motif and a Novel Cytosolic Motif Are Required for the Lysosomal and Melanosomal Targeting of OA1. J. Cel Sci.119, 2003–2014. 10.1242/jcs.02930
151
PingY.-Q.MaoC.XiaoP.ZhaoR.-J.JiangY.YangZ.et al (2021). Structures of the Glucocorticoid-Bound Adhesion Receptor GPR97-Go Complex. Nature589, 620–626. 10.1038/s41586-020-03083-w
152
PlazinskaA.PlazinskiW.LuchowskiR.WnorowskiA.GrudzinskiW.GruszeckiW. I. (2017). Ligand-induced Action of the W2866.48 Rotamer Toggle Switch in the β2-adrenergic Receptor. Phys. Chem. Chem. Phys.20, 581–594. 10.1039/c7cp04808d
153
PreisingM.Op de LaakJ. P.LorenzB. (2001). Deletion in the OA1 Gene in a Family with Congenital X Linked Nystagmus. Br. J. Ophthalmol.85, 1098–1103. 10.1136/bjo.85.9.1098
154
PrioleauC.VisiersI.EbersoleB. J.WeinsteinH.SealfonS. C. (2002). Conserved helix 7 Tyrosine Acts as a Multistate Conformational Switch in the 5HT2C Receptor. Identification of a Novel “Locked-on” Phenotype and Double Revertant Mutations. J. Biol. Chem.277, 36577–36584. 10.1074/jbc.M206223200
155
RabeyJ. M.HeftiF. (1990). Neuromelanin Synthesis in Rat and Human Substantia Nigra. J. Neural Transm. Park. Dis. Dement. Sect.2, 1–14. 10.1007/BF02251241
156
Ramos-ÁlvarezI.ManteyS. A.NakamuraT.Nuche-BerenguerB.MorenoP.MoodyT. W.et al (2015). A Structure-Function Study of PACAP Using Conformationally Restricted Analogs: Identification of PAC1 Receptor-Selective PACAP Agonists. Peptides66, 26–42. 10.1016/j.peptides.2015.01.009
157
RaposoG.TenzaD.MurphyD. M.BersonJ. F.MarksM. S. (2001). Distinct Protein Sorting and Localization to Premelanosomes, Melanosomes, and Lysosomes in Pigmented Melanocytic Cells✪. J. Cel Biol.152, 809–824. 10.1083/jcb.152.4.809
158
Rask-AndersenM.MasuramS.SchiöthH. B. (2014). The Druggable Genome: Evaluation of Drug Targets in Clinical Trials Suggests Major Shifts in Molecular Class and Indication. Annu. Rev. Pharmacol. Toxicol.54, 9–26. 10.1146/annurev-pharmtox-011613-135943
159
RasmussenS. G. F.DeVreeB. T.ZouY.KruseA. C.ChungK. Y.KobilkaT. S.et al (2011). Crystal Structure of the β2 Adrenergic Receptor-Gs Protein Complex. Nature477, 549–555. 10.1038/nature10361
160
RosenbaumD. M.RasmussenS. G. F.KobilkaB. K. (2009). The Structure and Function of G-Protein-Coupled Receptors. Nature459, 356–363. 10.1038/nature08144
161
RothB. L.IrwinJ. J.ShoichetB. K. (2017). Discovery of New GPCR Ligands to Illuminate New Biology. Nat. Chem. Biol.13, 1143–1151. 10.1038/nchembio.2490
162
SamaraweeraP.ShenB.NewtonJ. M.BarshG. S.OrlowS. J. (2001). The Mouse Ocular Albinism 1 Gene Product Is an Endolysosomal Protein. Exp. Eye Res.72, 319–329. 10.1006/exer.2000.0962
163
Sanchez-ReyesO. B.CookeA. L. G.TranterD. B.RashidD.EilersM.ReevesP. J.et al (2017). G Protein-Coupled Receptors Contain Two Conserved Packing Clusters. Biophys. J.112, 2315–2326. 10.1016/j.bpj.2017.04.051
164
SchiaffinoM. V.d’AddioM.AlloniA.BaschirottoC.ValettiC.CorteseK.et al (1999). Ocular Albinism: Evidence for a Defect in an Intracellular Signal Transduction System. Nat. Genet.23, 108–112. 10.1038/12715
165
SchiaffinoM. V. (2010). Signaling Pathways in Melanosome Biogenesis and Pathology. Int. J. Biochem. Cel Biol.42, 1094–1104. 10.1016/j.biocel.2010.03.023
166
SchiaffinoM. V.TacchettiC. (2005). The Ocular Albinism Type 1 (OA1) Protein and the Evidence for an Intracellular Signal Transduction System Involved in Melanosome Biogenesis. Pigment Cel Res18, 227–233. 10.1111/j.1600-0749.2005.00240.x
167
SchiöthH. B.FredrikssonR. (2005). The GRAFS Classification System of G-Protein Coupled Receptors in Comparative Perspective. Gen. Comp. Endocrinol.142, 94–101. 10.1016/j.ygcen.2004.12.018
168
SchneiderE. H.SchnellD.StrasserA.DoveS.SeifertR. (2010). Impact of the DRY Motif and the Missing “Ionic Lock” on Constitutive Activity and G-Protein Coupling of the Human Histamine H4 Receptor. J. Pharmacol. Exp. Ther.333, 382–392. 10.1124/jpet.109.163220
169
ScholzN.LangenhanT.SchönebergT. (2019). Revisiting the Classification of Adhesion GPCRs. Ann. N. Y. Acad. Sci.1456, 80–95. 10.1111/nyas.14192
170
SchöneggeA.-M.GallionJ.PicardL.-P.WilkinsA. D.Le GouillC.AudetM.et al (2017). Evolutionary Action and Structural Basis of the Allosteric Switch Controlling β2AR Functional Selectivity. Nat. Commun.8, 2169. 10.1038/s41467-017-02257-x
171
SchwinnG.SchwarckH.McIntoshC.MilstreyH. R.WillmsB.KöbberlingJ. (1976). Effect of the Dopamine Receptor Blocking Agent Pimozide on the Growth Hormone Response to Arginine and Exercise and on the Spontaneous Growth Hormone Fluctuations. J. Clin. Endocrinol. Metab.43, 1183–1185. 10.1210/jcem-43-5-1183
172
SeijiM.ShimaoK.BirbeckM. S.FitzpatrickT. B. (1963). Subcellular Localization of Melanin Biosynthesis. Ann. N. Y. Acad. Sci.100, 497–533. 10.1111/j.1749-6632.1963.tb42869.x
173
ShenB.SamaraweeraP.RosenbergB.OrlowS. J. (2001). Ocular Albinism Type 1: More Than Meets the Eye. Pigment Cel Res14, 243–248. 10.1034/j.1600-0749.2001.140403.x
174
ShionoT.TsunodaM.ChidaY.NakazawaM.TamaiM. (1995). X Linked Ocular Albinism in Japanese Patients. Br. J. Ophthalmol.79, 139–143. 10.1136/bjo.79.2.139
175
SiegelR. L.MillerK. D.JemalA. (2020). Cancer Statistics, 2020. CA Cancer J. Clin.70, 7–30. 10.3322/caac.21590
176
ŠimićG. (20192019). Heines DE. Neuroanatomy Atlas in Clinical Context: Structures, Sections, Systems, and Syndromes10th Edition. Baltimore: Wolters Kluwer Lippincott Williams Wilkins, 384. 10.3325/cmj.2019.60.390
177
SitaramA.MarksM. S. (2012). Mechanisms of Protein Delivery to Melanosomes in Pigment Cells. Physiology27, 85–99. 10.1152/physiol.00043.2011
178
SmithS. O. (2021). Deconstructing the Transmembrane Core of Class A G Protein-Coupled Receptors. Trends Biochem. Sci.46, 1017–1029. 10.1016/j.tibs.2021.08.006
179
SokoloffP.AndrieuxM.BesançonR.PilonC.MartresM. P.GirosB.et al (1992). Pharmacology of Human Dopamine D3 Receptor Expressed in a Mammalian Cell Line: Comparison with D2 Receptor. Eur. J. Pharmacol.225, 331–337. 10.1016/0922-4106(92)90107-7
180
SoneM.OrlowS. J. (2007). The Ocular Albinism Type 1 Gene Product, OA1, Spans Intracellular Membranes 7 Times. Exp. Eye Res.85, 806–816. 10.1016/j.exer.2007.08.016
181
SpatzA.BorgC.FeunteunJ. (2004). X-chromosome Genetics and Human Cancer. Nat. Rev. Cancer4, 617–629. 10.1038/nrc1413
182
StalevaL.OrlowS. J. (2006). Ocular Albinism 1 Protein: Trafficking and Function when Expressed in Saccharomyces cerevisiae. Exp. Eye Res.82, 311–318. 10.1016/j.exer.2005.07.003
183
StandfussJ.EdwardsP. C.D’AntonaA.FransenM.XieG.OprianD. D.et al (2011). The Structural Basis of Agonist-Induced Activation in Constitutively Active Rhodopsin. Nature471, 656–660. 10.1038/nature09795
184
StraussO. (2005). The Retinal Pigment Epithelium in Visual Function. Physiol. Rev.85, 845–881. 10.1152/physrev.00021.2004
185
SummersC. G.ConnettJ. E.HolleschauA. M.AndersonJ. L.De BeckerI.McKayB. S.et al (2014). Does Levodopa Improve Vision in Albinism? Results of a Randomized, Controlled Clinical Trial. Clin. Exp. Ophthalmol.42, 713–721. 10.1111/ceo.12325
186
TehanB. G.BortolatoA.BlaneyF. E.WeirM. P.MasonJ. S. (2014). Unifying Family A GPCR Theories of Activation. Pharmacol. Ther.143, 51–60. 10.1016/j.pharmthera.2014.02.004
187
Tombran-TinkJ.ShivaramS. M.ChaderG. J.JohnsonL. V.BokD. (1995). Expression, Secretion, and Age-Related Downregulation of Pigment Epithelium-Derived Factor, a Serpin with Neurotrophic Activity. J. Neurosci.15, 4992–5003. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7623128. 10.1523/jneurosci.15-07-04992.1995
188
TraboulsiE. I. (2012). Genetic Diseases of the Eye. USA: Oxford University Press. Available at: https://play.google.com/store/books/details?id=Yq-TISoByisC.
189
TrzaskowskiB.LatekD.YuanS.GhoshdastiderU.DebinskiA.FilipekS. (2012). Action of Molecular Switches in GPCRs-Ttheoretical and Experimental Studies. Curr. Med. Chem.19, 1090–1109. 10.2174/092986712799320556
190
UedaS.MasukawaD.KogaM.GoshimaY. (2016). l-3,4-Dihydroxyphenylalanine Induces Ptosis through a GPR143-independent Mechanism in Mice. J. Pharmacol. Sci.132, 109–112. 10.1016/j.jphs.2016.08.005
191
UhlénM.FagerbergL.HallströmB. M.LindskogC.OksvoldP.MardinogluA.et al (2015). Proteomics. Tissue-Based Map of the Human Proteome. Science347, 1260419. 10.1126/science.1260419
192
UhlenM.ZhangC.LeeS.SjöstedtE.FagerbergL.BidkhoriG.et al (2017). A Pathology Atlas of the Human Cancer Transcriptome. Science357. 10.1126/science.aan2507
193
Valentin-HansenL.GroenenM.NygaardR.FrimurerT. M.HollidayN. D.SchwartzT. W. (2012). The Arginine of the DRY Motif in Transmembrane Segment III Functions as a Balancing Micro-switch in the Activation of the β2-adrenergic Receptor. J. Biol. Chem.287, 31973–31982. 10.1074/jbc.M112.348565
194
Van LaereA.-S.CoppietersW.GeorgesM. (2008). Characterization of the Bovine Pseudoautosomal Boundary: Documenting the Evolutionary History of Mammalian Sex Chromosomes. Genome Res.18, 1884–1895. 10.1101/gr.082487.108
195
VenkatakrishnanA. J.DeupiX.LebonG.HeydenreichF. M.FlockT.MiljusT.et al (2016). Diverse Activation Pathways in Class A GPCRs Converge Near the G-Protein-Coupling Region. Nature536, 484–487. 10.1038/nature19107
196
VenkatakrishnanA. J.DeupiX.LebonG.TateC. G.SchertlerG. F.BabuM. M. (2013). Molecular Signatures of G-Protein-Coupled Receptors. Nature494, 185–194. 10.1038/nature11896
197
VetriniF.AuricchioA.DuJ.AngelettiB.FisherD. E.BallabioA.et al (2004). The Microphthalmia Transcription Factor (Mitf) Controls Expression of the Ocular Albinism Type 1 Gene: Link between Melanin Synthesis and Melanosome Biogenesis. Mol. Cel. Biol.24, 6550–6559. 10.1128/MCB.24.15.6550-6559.2004
198
VickeryO. N.CarvalhedaC. A.ZaidiS. A.PisliakovA. V.KatritchV.ZachariaeU. (2018). Intracellular Transfer of Na+ in an Active-State G-Protein-Coupled Receptor. Structure26, 171–180. 10.1016/j.str.2017.11.013
199
VisiersI.BallesterosJ. A.WeinsteinH. (2002). Three-dimensional Representations of G Protein-Coupled Receptor Structures and Mechanisms. Methods Enzymol.343, 329–371. 10.1016/s0076-6879(02)43145-x
200
WangX.-F.ChenH.HuangP.-J.FengZ.-K.HuaZ.-Q.FengX.et al (2021). Genotype-Phenotype Analysis and Mutation Spectrum in a Cohort of Chinese Patients with Congenital Nystagmus. Front Cel Dev Biol9, 627295. 10.3389/fcell.2021.627295
201
WeinsteinH. (2006). Hallucinogen Actions on 5-HT Receptors Reveal Distinct Mechanisms of Activation and Signaling by G Protein-Coupled Receptors. AAPS J.7, E871–E884. 10.1208/aapsj070485
202
WhiteK. L.EddyM. T.GaoZ.-G.HanG. W.LianT.DearyA.et al (2018). Structural Connection between Activation Microswitch and Allosteric Sodium Site in GPCR Signaling. Structure26, 259–269. 10.1016/j.str.2017.12.013
203
WilliamsS. E. I. (2018). “Albinism and the Eye,” in Albinism in Africa (Elsevier), 135–149. Available at: https://www.sciencedirect.com/science/article/pii/B9780128133163000076. 10.1016/b978-0-12-813316-3.00007-6
204
WinderA.KobayashiT.TsukamotoK.UrabeK.ArocaP.KameyamaK.et al (1994). The Tyrosinase Gene Family-Iinteractions of Melanogenic Proteins to Regulate Melanogenesis. Cell. Mol. Biol. Res.40, 613–626. Available at: https://www.ncbi.nlm.nih.gov/pubmed/7787879.
205
WongL.O’DonnellF. E.Richard GreenW. (1983). Giant Pigment Granules in the Retinal Pigment Epithelium of a Fetus with X-Linked Ocular Albinism. Ophthalmic Paediatr. Genet.2, 47–65. 10.3109/13816818309007149
206
WoottenD.SimmsJ.MillerL. J.ChristopoulosA.SextonP. M. (2013). Polar Transmembrane Interactions Drive Formation of Ligand-specific and Signal Pathway-Biased Family B G Protein-Coupled Receptor Conformations. Proc. Natl. Acad. Sci. U. S. A.110, 5211–5216. 10.1073/pnas.1221585110
207
XiaH.HuQ.LiL.TangX.ZouJ.HuangL.et al (2019). Protective Effects of Autophagy against Blue Light-Induced Retinal Degeneration in Aged Mice. Sci. China Life Sci.62, 244–256. 10.1007/s11427-018-9357-y
208
XiaR.MaoZ.-H. (2012). Progression of Motor Symptoms in Parkinson’s Disease. Neurosci. Bull.28, 39–48. 10.1007/s12264-012-1050-z
209
XingZ.WuS.ZangQ.LeiH.WeiY.ZhangC.et al (2021). GPR143 Is a Prognostic Biomarker Associated with Immune Infiltration in Melanoma. Res. Square. 10.21203/rs.3.rs-430494/v1
210
YamaguchiY.HearingV. J. (2014). Melanocytes and Their Diseases. Cold Spring Harb. Perspect. Med.4. 10.1101/cshperspect.a017046
211
YeL.NealeC.SljokaA.LydaB.PichuginD.TsuchimuraN.et al (2018). Mechanistic Insights into Allosteric Regulation of the A2A Adenosine G Protein-Coupled Receptor by Physiological Cations. Nat. Commun.9, 1372. 10.1038/s41467-018-03314-9
212
YoshiikeT.ManabeM.HayakawaM.OgawaH. (1985). Macromelanosomes in X-Linked Ocular Albinism (XLOA). Acta Derm. Venereol.65, 66–69. Available at: https://www.ncbi.nlm.nih.gov/pubmed/2578709.
213
YoungA.PowelsonE. B.WhitneyI. E.RavenM. A.NusinowitzS.JiangM.et al (2008). Involvement of OA1, an Intracellular GPCR, and G Alpha I3, its Binding Protein, in Melanosomal Biogenesis and Optic Pathway Formation. Invest. Ophthalmol. Vis. Sci.49, 3245–3252. 10.1167/iovs.08-1806
214
YuanS.FilipekS.PalczewskiK.VogelH. (2014). Activation of G-Protein-Coupled Receptors Correlates with the Formation of a Continuous Internal Water Pathway. Nat. Commun.5, 4733. 10.1038/ncomms5733
215
YuanS.VogelH.FilipekS. (2013). The Role of Water and Sodium Ions in the Activation of the μ-opioid Receptor. Angew. Chem. Int. Ed. Engl.52, 10112–10115. 10.1002/anie.201302244
216
YueJ. L.OkamuraH.GoshimaY.NakamuraS.GeffardM.MisuY. (1994). Baroreceptor-aortic Nerve-Mediated Release of Endogenous L-3,4-Dihydroxyphenylalanine and its Tonic Depressor Function in the Nucleus Tractus Solitarii of Rats. Neuroscience62, 145–161. 10.1016/0306-4522(94)90321-2
217
ZhangS. X.WangJ. J.GaoG.ParkeK.MaJ.-X. (2006). Pigment Epithelium-Derived Factor Downregulates Vascular Endothelial Growth Factor (VEGF) Expression and Inhibits VEGF-VEGF Receptor 2 Binding in Diabetic Retinopathy. J. Mol. Endocrinol.37, 1–12. 10.1677/jme.1.02008
218
ZhangX. C.CaoC.ZhouY.ZhaoY. (2015). Proton Transfer-Mediated GPCR Activation. Protein Cell6, 12–17. 10.1007/s13238-014-0106-4
219
ZhangX. C.SunK.ZhangL.LiX.CaoC. (2013). GPCR Activation: Protonation and Membrane Potential. Protein Cell4, 747–760. 10.1007/s13238-013-3073-2
220
ZhaoX.-M.LiY.-B.SunP.PuY.-D.ShanM.-J.ZhangY.-M. (2021). Bioinformatics Analysis of Key Biomarkers for Retinoblastoma. J. Int. Med. Res.49, 3000605211022210. 10.1177/03000605211022210
221
ZhouQ.YangD.WuM.GuoY.GuoW.ZhongL.et al (2019). Common Activation Mechanism of Class A GPCRs. Elife8. 10.7554/eLife.50279
222
ZhuW.-Y.TanC.ZhangR.-Z. (2018). Atlas of Skin Disorders: Challenging Presentations of Common to Rare Conditions. Springer Available at: https://play.google.com/store/books/details?id=g_pmDwAAQBAJ.
223
ZoccalD. B.FuruyaW. I.BassiM.ColombariD. S. A.ColombariE. (2014). The Nucleus of the Solitary Tract and the Coordination of Respiratory and Sympathetic Activities. Front. Physiol.5, 238. 10.3389/fphys.2014.00238
Summary
Keywords
orphan receptors, GPCRs (G protein-coupled receptors), GPR143, ocular albinism type 1 (OA1), melanosome, intracellular GPCR, pigment cells
Citation
Bueschbell B, Manga P and Schiedel AC (2022) The Many Faces of G Protein-Coupled Receptor 143, an Atypical Intracellular Receptor. Front. Mol. Biosci. 9:873777. doi: 10.3389/fmolb.2022.873777
Received
11 February 2022
Accepted
10 March 2022
Published
12 April 2022
Volume
9 - 2022
Edited by
George Khelashvili, Weill Cornell Medicine, Cornell University, United States
Reviewed by
Hideaki Yano, Northeastern University, United States
Tony Ngo, Sanford Burnham Prebys Medical Discovery Institute, United States
Updates
Copyright
© 2022 Bueschbell, Manga and Schiedel.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anke C. Schiedel, schiedel@uni-bonn.de
This article was submitted to Structural Biology, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.